Behavioral Health Phase 1, 2012

FINAL REPORT
December 27, 2012
## Contents

Introduction ............................................................................................................................................................ 3  
Measure Evaluation ................................................................................................................................................ 4  
  Overarching Issues .......................................................................................................................................... 4  
Recommendations for Future Measure Development ........................................................................................... 9  
Measure Evaluation Tables ..................................................................................................................................... 9  
  Measures Endorsed....................................................................................................................................... 11  
  Measures Not Endorsed................................................................................................................................ 33  
  Measures Deferred....................................................................................................................................... 34  
  Withdrawn From Consideration .................................................................................................................... 34  
Endnotes ............................................................................................................................................................... 35  
Appendix A – Measure Specifications ................................................................................................................... 36  
Appendix B – Steering Committee ........................................................................................................................ 63  
Appendix C – Related Measure Comparison Tables ............................................................................................. 66
Behavioral Health Phase 1, 2012

FINAL REPORT

Introduction

The Affordable Care Act (ACA) calls for the establishment of a National Strategy for Quality Improvement in Health Care to include national priorities and a strategic plan for improving the delivery of health care services, achieving better consumer outcomes, and improving the health of the U.S. population. Similarly, the Substance Abuse and Mental Health Services Administration (SAMHSA) is now advancing a national Framework for Quality Improvement in Behavioral Health Care, aimed at establishing national priorities, goals, and opportunities for: improving the delivery of behavioral health services, achieving better behavioral health outcomes, and improving the behavioral health of the U.S. population, especially those with mental illnesses and substance abuse. Behavioral health refers to a state of mental or emotional being and choices and actions that affect wellness, as defined in the Substance Abuse Mental Health Services Administration (SAMHSA) National Behavioral Health Quality Framework (NBHQF)\(^1\). Behavioral health problems include substance abuse or misuse, alcohol and drug addiction, serious psychological distress, suicide, and mental and substance use disorders.

In the United States, it is estimated that approximately 26.4 percent of the population suffers from mental illness and substance abuse.\(^2\) While mental illness is prevalent throughout the general population, the substantial burden of disease is concentrated in the 6 percent who suffer from a serious mental illness. Such individuals are now dying 25 years earlier than the general population.\(^3\) Although most of the years of lost life can be attributed to medical illnesses, an individual’s mental health status has a significant impact on engagement in treatment of medical conditions, therapeutic response, and overall outcomes.\(^4\)

The NQF-convened Measure Applications Partnership (MAP), which was created to provide input to the Department of Health and Human Services (HHS) on the selection of performance measures for public reporting and performance-based payment programs, was tasked by HHS to examine quality issues affecting the heterogeneous Medicare-Medicaid dual eligible beneficiary population and to provide input on an appropriate measurement strategy. The MAP identified five high-leverage opportunity areas in which measurement can have the most significant positive effects. Mental health and substance use is one of those areas, along with quality of life, screening and assessment, care coordination, and structural measures. The MAP has put forward a set of available measures considered core for use with this population, a quarter of which are related to behavioral health.

To date, NQF has endorsed a relatively small proportion of measures, approximately 45, specific to mental health or substance abuse. This multi-phase project is aimed at endorsing measures of accountability for improving the delivery of behavioral health services, achieving better behavioral health outcomes, and improving the behavioral health of the U.S. population, especially those with mental illness and substance abuse.\(^5\)

In Phase I, NQF sought to endorse behavioral health measures of process, outcomes and structure that serve as indicators of quality behavioral healthcare across all care delivery settings, including primary and specialty care. In Phase 2, NQF will seek to endorse additional measures addressing gap areas identified in Phase 1. NQF-endorsed® standards relating to behavioral healthcare that are due for endorsement maintenance also will be reviewed.
Measure Evaluation

To facilitate evaluation of a large number of measures, the project was divided into phases. In the first phase, the Behavioral Health Steering Committee reviewed candidate standards relating to tobacco and alcohol use screening and follow-up care, as well as screening and medication management for individuals with schizophrenia and bipolar disease. The Committee and the candidate standards were divided into three workgroups for a preliminary review of measures against the evaluation sub-criteria prior to evaluation by the entire Steering Committee. At the in-person meeting on April 17-18, 2012, the Committee evaluated eighteen new measures (two of which were ultimately combined into one measure) and four measures undergoing endorsement maintenance review against NQF’s Measure Evaluation Criteria. The Committee’s discussion and rating of the criteria are summarized in the evaluation tables beginning on page A-1.

Table 1: Behavioral Health Phase 1 Summary

<table>
<thead>
<tr>
<th></th>
<th>Maintenance</th>
<th>New</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measures under consideration</td>
<td>4</td>
<td>18</td>
<td>22</td>
</tr>
<tr>
<td>Measures deferred</td>
<td>0</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Withdrawn from consideration</td>
<td>0</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Recommended</td>
<td>4</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>Not recommended</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Reasons for Not Recommending</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Overarching Issues

During the Steering Committee’s discussion of the measures, several overarching issues emerged that were factored into the Committee’s ratings and recommendations. These issues are discussed in detail in the following sections.

Evidence and Measure Testing (Reliability and Validity)

The Steering Committee noted that NQF criteria have become more rigorous following the 2010 task force recommendations regarding evaluating evidence and testing. Reviewing the measures as a whole, Committee members suggested that in the future developers more clearly delineate how structure-process-outcome are linked when providing evidence to support the measures, and ensure that the testing provided can demonstrate reliability and validity of the measures.

For the sets of measures relating to tobacco use and alcohol use, the Committee strongly agreed that there is a need for measures in this area and generally agreed the measures were important to measure and report. Because the testing provided for newly submitted tobacco and alcohol measures showed lower than desired reliability, the consensus of the Committee was that Scientific Acceptability was not met. The Committee strongly encouraged the developer, the Joint Commission, to continue to refine and test the measures and re-submit them. The Joint Commission indicated that they are continuing to test the measures and will provide additional testing data to the Steering Committee in time for the measures to continue through the endorsement process in Phase 2 of the project. The measures have been deferred for further consideration until that time.
Harmonization of Related Measures

Related measures identified within this phase include: adherence to antipsychotic medication for individuals with schizophrenia, screening, assessment and monitoring measures for individuals with schizophrenia and bipolar disease. Please see the side-by-side tables of specifications in Appendix C.

Measure Group 1

#1879 Adherence to Oral Antipsychotics for Individuals with Schizophrenia (CMS)

#1935 Use of Antipsychotic Medication (NCQA)

#1936 Continuity of Antipsychotic Medications for Treatment of Schizophrenia (NCQA)

The Steering Committee evaluated three similar measures related to adherence to antipsychotic medication for patients with schizophrenia (#1879 and measure pair #1935 and #1936) and agreed it was preferable to recommend a single, harmonized measure rather than multiple, overlapping measures. There were several differences in the measures that the developers, Centers for Medicare and Medicaid Services (CMS) and the National Committee for Quality Assurance (NCQA), worked together to resolve during the course of the Committee’s review and during the member and public comment period.

As a result of their work, measure #1935 has been withdrawn from consideration and measures #1936 and #1879 have been combined into one harmonized measure, #1879 Adherence to Antipsychotic Medications for Individuals with Schizophrenia stewarded by CMS. With the elements of #1936 incorporated into #1879, #1936 is considered withdrawn.

Resolved differences include:

- **Differing target populations.** The Steering Committee recommended that a harmonized measure target individuals aged 18 years and older (as specified in #1879) rather than 25 years (as specified in #1935 and #1936). Steering Committee members alternatively suggested a separate ‘first episode’ measure.
  - The harmonized measure specifies individuals aged 18 years and older, as is currently defined in #1879. A separate ‘first episode’ measure is not recommended at this time.

- **Differing claims for prescriptions in denominator.** There were differences in the measures on whether or not the denominator required two separate inpatient claims or one inpatient claim with a prescription for antipsychotics (#1935, #1936) or two outpatient, inpatient, emergency department setting encounters (#1879). The Steering Committee suggested including two prescription fills in the measurement period as done in #1879.
  - The harmonized measure specifies two prescription fills required in the denominator, as is currently defined in #1879.

- **Differing exclusions.** One measure excluded injectable drugs and dementia patients (#1879), while the measure pair did not (#1935 and #1936). The Committee suggested a harmonized measure include injectable drugs, and exclude dementia and pregnancy.
  - **Injectable drugs.** The developers agreed to include individuals receiving long-acting injectable medications in the harmonized measure which would make the measure applicable to a broader population of patients with schizophrenia.
- **Dementia.** The developers agreed to retain the exclusion for dementia in #1879, and NCQA will align codes in their HEDIS measure ("Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a diagnosis of dementia and a prescription for tricyclic antidepressants or anticholinergic agents") to identify a dementia diagnosis.

- **Pregnancy.** The developers determined that pregnancy is not an absolute contraindication for medication adherence, that the benefits of including this population outweighed the harms, and did not exclude pregnancy in the measures.

**Other:**

- **Schizoaffective disorder, clarification.** The Steering Committee recommended that the developers modify specifications language to clarify that schizoaffective disorder is included in the measure. Schizoaffective disorder is included in ICD-9-CM/ICD-10-CM codes as specified in #1879 and #1936. The developers modified the wording in the specifications for the measure to ensure that it is clear that schizoaffective disorder is included.

- **Adherence methodology.** The Steering Committee recommended that the developers review the standard methods for assessing medication adherence, referencing the NQF Medication Management Report and determine whether a recommendation could be made regarding the best approach, and questioned whether the threshold of 80 percent adherence rate in the measures was optimal. The developers determined that testing shows the method of proportion of days covered (PDC) was the best approach as it has a higher face and translational validity than the standard medication possession ratio (MPR), and noted that PDC has been adopted by other NQF-endorsed adherence measures as a standard methodology. The developers recommend the measure remain specified with the PDC methodology. The developers also determined that several studies link improved outcomes to adherence to antipsychotics used a threshold of 80 percent. In addition, existing NQF-endorsed adherence measures #541, #542, #543, and #545 use 80 percent as the appropriate threshold for other chronically administered medications. The developers recommend that the threshold for adherence remain at 80 percent as specified.

- **Measure pair.** Steering Committee suggested one measure rather than the #1935 and #1936 pair. The developer agreed and requested measure #1935 be removed from consideration for endorsement due to the high performance seen in their testing data.

**Measure Group 2**

#0003 Bipolar Disorder: Assessment for diabetes (Centers for Quality Assessment and Improvement in Mental Health)

#1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (SSD) (NCQA)

The Steering Committee evaluated and recommended for endorsement a new measure related to screening and assessing individuals with schizophrenia and bipolar disease for diabetes (#1932). The Steering Committee also recommended harmonization of the new measure #1932 with existing NQF endorsed measure #0003. Differences in the existing and new measure are shown below.
<table>
<thead>
<tr>
<th></th>
<th>#0003 Bipolar Disorder: Assessment for diabetes (Centers for Quality Assessment and Improvement in Mental Health)</th>
<th>#1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (SSD) (NCQA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of Analysis</td>
<td>Specified at the individual and group physician level</td>
<td>Specified at the plan and state level</td>
</tr>
<tr>
<td>Patient Population</td>
<td>Patients 18 years or older with bipolar disorder assessed for diabetes within 16 weeks after initiating treatment with an atypical medication</td>
<td>Patients 25 to 64 years with bipolar disorder or prescribed either an atypical or typical medication who received a diabetes screening during the measurement year</td>
</tr>
<tr>
<td>Exclusions</td>
<td>No exclusions</td>
<td>Patients are excluded if they already have diabetes</td>
</tr>
<tr>
<td>Data Source</td>
<td>Claims data and chart abstraction</td>
<td>Claims data only</td>
</tr>
</tbody>
</table>

The areas for harmonization include levels of analysis at the individual or group clinical level vs. the state level; the inclusion of those aged 18 and older vs. those aged 25 to 64, the exclusion of patients with diabetes, and the use of a combination of claims data and chart abstraction vs. claims data only. Harmonization of the measures is requested within 12 months of endorsement.

**Measure Group 3**

**#0057 Diabetes: Hemoglobin A1c testing (NCQA)**

**#0063 Diabetes: Lipid profile (NCQA)**

**#1934 Diabetes monitoring for people with diabetes and schizophrenia (SMD) (NCQA)**

The Steering Committee evaluated a new measure on diabetes monitoring of individuals with schizophrenia (#1934). The measure addresses a subset of two existing measures for patients with a diagnosis of diabetes. The Committee agreed that the new measure is suitable for endorsement; however, as recommended by the Steering Committee, the developer, NCQA agreed to incorporate the new measure as subsets or target populations within the more broadly defined NQF endorsed measures (#0057 and #0063) following the member voting period and CSAC/Board reviews. Please see the side-by-side tables of specifications in Appendix C. Differences in the existing and new measures are shown below.
<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Measure Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>#0057</td>
<td>Diabetes: Hemoglobin A1c testing (NCQA)</td>
</tr>
<tr>
<td>#0063</td>
<td>Diabetes: Lipid profile (NCQA)</td>
</tr>
<tr>
<td>#1934</td>
<td>Diabetes monitoring for people with diabetes and schizophrenia (SMD) (NCQA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level of Analysis</th>
<th>Specified at the clinician, health plan, and population level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of Analysis</td>
<td>Specified at the individual and group physician level, plan, delivery system, national, regional, and state level</td>
</tr>
<tr>
<td>Level of Analysis</td>
<td>Specified at the population level</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Patients 18 to 75 receiving at least one A1c test per year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Population</td>
<td>Patients 18 to 75 with a diagnosis of diabetes and an LDL-C test performed during the measurement year</td>
</tr>
<tr>
<td>Patient Population</td>
<td>Patients 25 to 64 with schizophrenia receiving an HbA1c test and LDL-C test during the measurement year</td>
</tr>
</tbody>
</table>

| Exclusions | Exclude patients with a diagnosis of polycystic ovaries and patients with a diagnosis of gestational diabetes or steroid-induced diabetes on the problem list, who did not have a diagnosis of diabetes on the problem list during the measurement year or year prior to the measurement year |
| Exclusions | No exclusions |
| Exclusions | No exclusions |

<table>
<thead>
<tr>
<th>Data Source</th>
<th>Claims data and chart abstraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Source</td>
<td>Claims data and chart abstraction</td>
</tr>
<tr>
<td>Data Source</td>
<td>Claims data only</td>
</tr>
</tbody>
</table>

The areas for harmonization across the three measures include the levels of testing at the individual and group clinician, health plan, delivery system, national regional and state population levels vs. analysis only at the population level, inclusion of those aged 18 and older with either an A1c or an LDL-C test performed vs. those aged 25 to 64 with both tests performed, the exclusion of patients with polycystic ovaries and gestational diabetes or steroid-induced diabetes on the problem list, who did not have diabetes vs. no exclusions, and the use of a combination of claims data and chart abstraction vs. claims data only.

**Measure Group 4**

**0576 Follow-up After Hospitalization for Mental Illness (NCQA)**

**1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)**

The Steering Committee also evaluated and recommended for endorsement an existing measure and a new measure related to follow-up after hospitalization for mental illness (#0576 and #1937). The Steering Committee recommended that the developer incorporate the new measure #1937 as a subset or target population within the more broadly defined measure #0576, and the developer, NCQA, agreed to do so following the member voting period and CSAC/Board reviews. Please see the side-by-side tables of specifications in Appendix C. Differences in the existing and new measure are shown below.
<table>
<thead>
<tr>
<th>Level of Analysis</th>
<th>0576 Follow-up After Hospitalization for Mental Illness (NCQA)</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specified at the plan, clinician team and integrated delivery system, and local, nation, regional and state levels</td>
<td>Specified at the state level</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>0576 Follow-up After Hospitalization for Mental Illness (NCQA)</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients 6 years and older discharged from an acute inpatient setting with a principal mental health diagnosis during the measurement year, who received follow-up within 7- and 30-days of discharge</td>
<td>Patients 25 to 64 years of age discharged after hospitalization for treatment of schizophrenia during the measurement year, who received follow-up within 7- and 30-days of discharge</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusions</th>
<th>0576 Follow-up After Hospitalization for Mental Illness (NCQA)</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain discharge, readmission and transfer discharges that may prevent an outpatient follow-up visit from taking place</td>
<td>Certain discharge, readmission and transfer discharges that may prevent an outpatient follow-up visit from taking place</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data Source</th>
<th>0576 Follow-up After Hospitalization for Mental Illness (NCQA)</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative claims, EHRs</td>
<td>Administrative claims.</td>
<td></td>
</tr>
</tbody>
</table>

The areas for harmonization include levels of analysis at the plan, clinician team and integrated delivery system, and local, nation, regional and state levels vs. the state level only; the inclusion of those aged 6 and older discharged after hospitalization with a principal mental health diagnosis vs. those aged 25 to 64 discharged after hospitalization for treatment of schizophrenia, and the use of a combination of administrative claims and EHR data vs. administrative claims data only.

**Electronic Health Record Specifications**

The tobacco measure #0028 Preventive Care and Screening: Tobacco Use: Screening & Cessation Intervention (AMA-PCPI) was submitted with additional electronic specifications. The specifications underwent an eMeasure format review.

**Recommendations for Future Measure Development**

The Steering Committee recognized gaps in measurement in the areas of screening for alcohol and drugs, specifically using tools such as the Screening Brief Intervention and Referral to Treatment (SBIRT). Members also noted a gap in screening for post-traumatic stress disorder (PTSD) and bi-polar disorder in all patients diagnosed with depression, with an eye toward differentiating between the disorders.

**Measure Evaluation Tables**

**Measures Endorsed**

0004 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment ......................................................... 11
0027 Medical Assistance With Smoking and Tobacco Use Cessation..................................................................................... 14
0028 Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention ......................................................... 16
1879 Adherence to Antipsychotics for Individuals with Schizophrenia.................................................................................... 17
1936 Continuity of Antipsychotic Medications for Treatment of Schizophrenia ................................................................. 19
1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications .................................................................................................................. 19
1927 Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications .................................................................................................................................... 22
1933 Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia ............. 24
1934 Diabetes monitoring for people with diabetes and schizophrenia............................................................ 26
1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) ......................................................... 28
0576 Follow-Up After Hospitalization for Mental Illness ...................................................................................... 30

Measures Not Endorsed
1938 Emergency department utilization for mental health conditions by people with schizophrenia .......... 33

Measures Deferred ....................................................................................................................................... 34

Withdrawn From Consideration .............................................................................................................. 34
# Measures Endorsed

## Alcohol Measures

<table>
<thead>
<tr>
<th>Measure Code</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>0004</td>
<td>Initiation and Engagement of Alcohol and Other Drug Dependence Treatment</td>
</tr>
</tbody>
</table>

### Maintenance Measure

**Description:** The percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) dependence who received the following.

a. Initiation of AOD Treatment. The percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis.

b. Engagement of AOD Treatment. The percentage of members who initiated treatment and who had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit.

**Numerator Statement:**

- If the Index Episode was an inpatient discharge, the inpatient stay is considered initiation of treatment and the member is compliant.
- If the Index Episode was an outpatient, intensive outpatient, partial hospitalization, detoxification or ED visit, the member must have an inpatient admission, outpatient visit, intensive outpatient encounter or partial hospitalization (Table IET-B) with an AOD diagnosis (Table IET-A) within 14 days of the IESD (inclusive).
  - If the initiation encounter is an inpatient admission, the admission date (not the discharge date) must be within 14 days of the IESD (inclusive).
- Do not count Index Episodes that include detoxification codes (including inpatient detoxification) as being initiation of treatment.

**Denominator Statement:** Members age 13 years of age and older with a medical and chemical dependency benefit who were diagnosed with a new episode of alcohol and drug dependency (AOD) during the intake period of January 1-November 15 of the measurement year. The Intake Period is used to capture new episodes of AOD.

**Exclusions:** Exclude members who had a claim/encounter with a diagnosis of AOD (Table IET-A) during the 60 days (2 months) before the IESD.

**Adjustment/Stratification:** No risk adjustment or risk stratification N/A

**Level of Analysis:** Health Plan, Integrated Delivery System, Population: County or City, Population: National, Population: Regional

**Type of Measure:** Process

**Data Source:** Administrative claims, Electronic Clinical Data: Electronic Health Record, Paper Medical Records

**Measure Steward:** National Committee for Quality Assurance

---

**Steering Committee In-Person April 17-18, 2012**
1. Importance to Measure and Report: The measure meets the Importance criteria.
(1a. High Impact: 1b. Performance Gap 1c. Evidence)

1a. Impact: H-15; M-4; L-0; I-0 1b. Performance Gap: H-5; M-10; L-3; I-1 1c. Evidence: Y-17; N-0; I-2

Rationale:
- The Committee agreed the measure is important because it seeks to increase access and quality of care. Steering committee members raised concerns regarding the clarity of the terms used in the numerator of the measure: the terms “abuse” and “dependence” are considered very different and the measure title and description are not clear: the title lists dependence initiation but it also measures abuse, making it not a true measure of dependence and addiction needing treatment.
  - The developer explained the measure is intended as an initiation and engagement measure and has been coded as such. They are currently looking into how those codes will change with the transition to ICD-10 and how abuse and dependence may be separated.
- The Committee questioned how the evidence supports the cited performance gap.
  - The developer explained the gap stratifies the population; however, the definition in the numerator may not be precise enough to be a true measure of the gap in both initiation and engagement. Steering committee members agreed there is a demonstrated performance gap.
- The Committee noted the evidence presented omits data on the capacity to identify and engage people in treatment. It does, however, show that those who are engaged have lower addiction severity index (ASI) scores over time.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-0; M-10; L-7; I-2 2b. Validity: H-0; M-13; L-3; I-3

Rationale:
- The Committee observed that when diagnoses are made in non-substance abuse clinics, there could be a high false positive rate for addiction visit types; this issue is further complicated with the inclusion of both abuse and dependence diagnoses in the measure.
- The Committee noted that the burden on providers to code the measure properly is concerning. Members were concerned about the large number of codes included in the measure, and also noted that most internists, family and primary care physicians do not routinely use the screening, brief intervention, referral and treatment (SBIRT) codes as most use the evaluation and management codes (E/M). Because the E/M codes are not included in the measure, it was a concern that many patients who should be included in the measure may not be captured with the current specifications. This variation in coding practices as well as the forthcoming DSM-V release led to some concerns with the reliability of the measure.
  - The developer explained that the intent of the broad use of codes and the broad measure was to capture the overlapping characteristics of the populations. The steering committee narrowly agreed the measure is reliable.
- The measure was field tested, presented to the CPM and incorporated into HEDIS in 2005.
- The Committee expressed a desire to see a single visit count in the measure and more data on disparities and minority groups, as well as vulnerable populations.

3. Usability: H-3; M-13; L-3; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)

Rationale:
- The measure is currently used for both public reporting and quality improvement.

4. Feasibility: H-2; M-15; L-2; I-0
(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- The data are readily available electronically.
### 0004 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment

**Rationale:**
- The committee found this measure to be suitable for NQF endorsement as it has demonstrated it is important, reliable and valid in order to be used to measure the initiation of alcohol and drug dependence treatment.

**RECOMMENDATIONS:**
- The committee was concerned about the use of the terms “abuse” and “dependence” in the measure and the potential threats to validity and reliability posed by the difference in the use of terms.
  - The developer will explore how this issue may be addressed with the move from ICD-9 to ICD-10.

**Public & Member Comment**
**Comments included:**
- One commenter requested clarification around the Committee’s discussion of reliability testing for this measure, noting that “the success in accounting for reliability concerns on varying terminology should be carefully considered upon future review.”

**Response:**
- Upon initial review of reliability testing for this measure, the Steering Committee was concerned given the use of both “abuse” and “dependence” in the measure. However, the Committee was ultimately satisfied with the developer’s explanation that the measure is broad because it intends to capture overlapping characteristics of the measure population.
  
  Further, the measure developer intends to revisit reliability testing when the expected publication of the DSM-V occurs in May of 2013 and the implementation of ICD-10-CM occurs in October 2014. In the future, when the measure has been updated to include these codes, changes may be provided to NQF during the annual update process, and if considered material changes, an ad hoc review can be initiated.

**CSAC Review**
Decision: Approved for continued endorsement

**BOD Review**
Decision: Ratified for continued endorsement
Tobacco Measures

0027 Medical Assistance With Smoking and Tobacco Use Cessation

Maintenance Measure

Description: Assesses different facets of providing medical assistance with smoking and tobacco use cessation:

Advising Smokers and Tobacco Users to Quit: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who received advice to quit during the measurement year.

Discussing Cessation Medications: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were recommended cessation medications during the measurement year.

Discussing Cessation Strategies: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were provided smoking cessation methods or strategies during the measurement year.

Numerator Statement: Component 1: Advising Smokers and Tobacco Users to Quit (ASTQ)
Received advice to quit smoking
Component 2: Discussing Cessation Medications (DSCM)
Received discussion/recommendations on smoking cessation medications
Component 3: Discussing Cessation Strategies (DSCS)
Received discussion/recommendations on smoking cessation methods and strategies

Denominator Statement: Patients 18 years and older who responded to the survey and indicated that they were current smokers or tobacco users

Exclusions: None

Adjustment/Stratification: No risk adjustment or risk stratification

Level of Analysis: Health Plan
Type of Measure: Process
Data Source: Patient Reported Data/Survey
Measure Steward: National Committee for Quality Assurance

Steering Committee In-Person April 17-18, 2012

1. Importance to Measure and Report: The measure meets the Importance criteria.
   (1a. High Impact: 1b. Performance Gap 1c. Evidence)
   1a. Impact: H-18; M-0; L-0; I-0
   1b. Performance Gap: H-12; M-6; L-0; I-0
   1c. Evidence: Y-18; N-1; I-0

Rationale:

• The importance of advising smokers to quit, offering recommendations and medication options is well established.
• The mean performance for this measure is 75 percent, demonstrating there is room for improvement.
• The evidence is based on the US Preventive Services Task Force recommendations.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   2a. Reliability: H-1; M-13; L-2; I-2
   2b. Validity: H-3; M-14; L-1; I-1

Rationale:

• Reliability of the measure score was examined using a beta-binomial model; a method to meaningfully distinguish reliability between plans.
• The Committee was concerned about the length of time between patient-physician interaction and when the survey is distributed: errors in patient recall over the measurement year could negatively impact reliability and validity.
  o The developer stated that surveys may be administered in a rolling fashion in the future to help minimize the time between interaction and survey, and explained that there is a recall bias but it is a shared bias.
• Two groups of experts examined the validity of the measure and found it to have face validity.
0027 Medical Assistance With Smoking and Tobacco Use Cessation

3. Usability: H-6; M-11; L-1; I-1
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)

Rationale:
- The measure has been in use within the CAHPS survey.

4. Feasibility: H-8; M-9; L-1; I-1
(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Committee members expressed some concern regarding recall bias; in some cases physician charts reflect a discussion with patients, but patients themselves may not recall the discussion when completing the survey.
  - The developer noted the concern and responded that there is some work in progress to possibly alter the methodology of administering CAHPS for this reason.

Steering Committee Recommendation on Overall Suitability for Endorsement: Y-17; N-2

Rationale:
- The Committee found this measure to be suitable for endorsement. The medical assistance component of smoking cessation is well grounded in the USPSTF evidence and the measure is in widespread use with CAHPS.

RECOMMENDATIONS:
- The Committee was concerned about the potential for recall bias in the collection of this measure due to the potential time elapsed between physician-patient interaction and the survey.
  - The developer expressed a desire to survey more frequently with the advent of new technology.

Public & Member Comment

Comments included:
- CMS expressed support for this measure, but questioned whether the retooled, e-specified version of the measure would also be considered endorsed.

Response:
- NQF clarified that the measure will only be endorsed for testing specifications that have currently been submitted and evaluated. Therefore, the e-specified version of this measure will not be considered endorsed. If, however, updated e-specifications of this measure are submitted during the annual update for the measure, the data source for the measure can be expanded to include electronic health record systems and the eMeasure specifications will be associated with the measure.

CSAC Review
Decision: Approved for continued endorsement

BOD Review
Decision: Ratified for continued endorsement
0028 Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention

**Maintenance Measure**

**Description:** Percentage of patients aged 18 years and older who were screened for tobacco use at least once during the two-year measurement period AND who received tobacco cessation counseling intervention if identified as a tobacco user.

**Numerator Statement:** Patients who were screened for tobacco use* at least once during the two-year measurement period AND who received tobacco cessation counseling intervention** if identified as a tobacco user.

*Includes use of any type of tobacco

**Denominator Statement:** All patients aged 18 years and older who were seen twice for any visits or who had at least one preventive care visit during the two-year measurement period.

**Exclusions:** Documentation of medical reason(s) for not screening for tobacco use (eg, limited life expectancy).

**Adjustment/Stratification:** No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

**Level of Analysis:** Clinician: Group/Practice, Clinician: Individual, Clinician: Team.

**Type of Measure:** Process.

**Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Pharmacy, Paper Medical Records.

**Measure Steward:** American Medical Association - convened Physician Consortium for Performance Improvement (AMA-convened PCPI).

**Steering Committee In-Person April 17-18, 2012**

1. **Importance to Measure and Report:** The measure meets the Importance criteria.

   (1a. High Impact: 1b. Performance Gap 1c. Evidence)

   **1a. Impact:** H-19; M-0; L-0; I-0 1b. Performance Gap: H-13; M-6; L-0; I-0 1c. Evidence: Y-17; N-1; I-1

   **Rationale:**

   - The Committee agreed that this measure represents a high-impact aspect of health care.
   - There are suboptimal rates of asking and advising to quit, as well as prescribing pharmacotherapy.
   - Even though the measure has been in use since 2003, there is still an opportunity for improvement.
   - Research has shown that increased counseling leads to increased quit rates; however, even brief counseling by physicians can have an impact on increasing quit rates.
   - Committee members raised concerns that the two-year follow up time window is too long.
     - The developer stated a two-year follow-up window was specified to reduce burden on patients. A physician may ask patients more frequently; however, only every two years is required for the measure. It is also specified for the same clinician, as denoted by the two visit criteria.

2. **Scientific Acceptability of Measure Properties:** The measure meets the Scientific Acceptability criteria.

   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

   **2a. Reliability:** H-8; M-11; L-0; I-0 2b. Validity: H-6; M-11; L-2; I-0

   **Rationale:**

   - The reliability at the average number of quality reporting events was stable, ranging from .86 to .88.
   - Face validity was conducted by an expert panel of 30 people.

3. **Usability:** H-15; M-3; L-1; I-0

   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting/Accountability and 3b. Quality Improvement)

   **Rationale:**

   - The measure has been reported as a part of the CMS PQRS program.
PREVENTIVE CARE & SCREENING: TOBACCO USE: SCREENING & CESSATION INTERVENTION

4. Feasibility: H-12; M-7; L-0; I-0

(4a. Clinical data generated during care delivery; 4b. Electronic sources; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Feasibility is acceptable using claims-based data and is expected to increase as more primary care practices incorporate electronic health records.

STEERING COMMITTEE RECOMMENDATION ON OVERALL SUITABILITY FOR ENDORSEMENT: Y-19; N-0

Rationale:
- The Committee found this measure suitable for endorsement. It is in widespread use with the PQRS program and despite being in use since 2003, still presents a significant opportunity for performance improvement.

RECOMMENDATIONS:
- Committee members expressed concern about the two-year time window and suggested additional data might aid in understanding the time window.
- Committee members suggested that including testing results showing how many actual minutes of counseling are most effective would be helpful.

PUBLIC & MEMBER COMMENT
Comments included:
- No comments were received for this measure.

CSAC REVIEW
Decision: Approved for continued endorsement

BOD REVIEW
Decision: Ratified for continued endorsement

MEDICATION MEASURES

1879 ADHERENCE TO ANTIPSYCHOTICS FOR INDIVIDUALS WITH SCHIZOPHRENIA

NOTE: This measure has now been combined with measure #1936 (Continuity of Antipsychotic Medications for Treatment of Schizophrenia). The single harmonized measure (#1879) will be stewarded by CMS.

New Measure

Description: The measure calculates the percentage of individuals 18 years of age or greater with schizophrenia who are prescribed an oral antipsychotic medication, with adherence to the antipsychotic medication (defined as a Proportion of Days Covered (PDC) of at least 0.8 during the measurement period (12 consecutive months).

Numerator Statement: Individuals with schizophrenia who filled at least two prescriptions for any oral antipsychotic medication and have a Proportion of Days Covered (PDC) for antipsychotic medications of at least 0.8.

Denominator Statement: Individuals at least 18 years of age as of the end of the measurement period with schizophrenia with at least two claims for any oral antipsychotic medication during the measurement period (12 consecutive months).

Exclusions: We excluded the following individuals from the denominator:
- EXCLUSION 1 Individuals who received an injection (including depot injections) for any antipsychotic medication during the measurement period.
- EXCLUSION 2 Individuals with any diagnosis of dementia during the measurement period

Adjustment/Stratification: N/A

Level of Analysis: Clinician: Group/Practice, Population: State

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data: Pharmacy, Other

Measure Steward: Centers for Medicare and Medicaid Services

STEERING COMMITTEE IN-PERSON APRIL 17-18, 2012
1879 Adherence to Antipsychotics for Individuals with Schizophrenia

1. Importance to Measure and Report: The measure meets the Importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   1a. Impact: H-16; M-3; L-0; I-0; 1b. Performance Gap: H-6; M-11; L-1; I-1; 1c. Evidence: Y-14, N-0, I-5
   **Rationale:**
   - This measure focuses on individuals with schizophrenia who have filled more than two antipsychotic prescriptions and have a proportion of days covered (PDC) greater than 80 percent; this is a high impact area as studies have shown individuals with schizophrenia often have poor compliance, which leads to increased rates of hospitalization.
   - There appears to be a significant performance gap as many studies document poor medication compliance in individuals with schizophrenia, particularly those 18 to 44 years of age. The data presented at the state level shows that there is variation with performance ranging from 67.5 percent to 84.7 percent.
   - Strong evidence was presented in support of maintenance of antipsychotic medications.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   2a. Reliability: H-2; M-14; L-1; I-2; 2b. Validity: H-2; M-14; L-0; I-3
   **Rationale:**
   - Reliability testing was conducted using a beta-binomial method at the state level and the measure received scores of .9, with “good” defined as greater than .7. The measure was more reliable for physician groups with greater than 45 patients with a diagnosis of schizophrenia than for those with less than 45 patients.
   - Face validity of the measure was demonstrated by a 12-member expert panel that evaluated the measure and either “strongly agreed” or “agreed” that the measure appears to measure what is intended.
   - Threats to validity include missing individuals paying cash for prescriptions (and therefore not being included in claims data) and missing data; however, the Committee agreed these were low threats to validity.

3. Usability: H-7; M-9; L-2; I-1
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)
   **Rationale:**
   - The Steering Committee agreed an adherence measure at both the state population and physician group level will help providers recognize patients that are not compliant. For those populations with low adherence the measure could also be used to develop interventions for these groups.
     - The developer explained its technical expert panel was also asked to assess the usability of this measure and all “strongly agreed” or “agreed” the measure is highly usable.

4. Feasibility: H-2; M-13; L-3; I-1
   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)
   **Rationale:**
   - Data is readily available and can be drawn from electronic claims.
   - Committee members noted a possible susceptibility to inaccuracies as a percentage of individuals will not be accounted for, due to free drug programs.
     - The developer stated this issue was also raised by its technical expert panel, as free drug programs are becoming more available. The measure developer will use the input and take a closer look at this issue.
1879 Adherence to Antipsychotics for Individuals with Schizophrenia

Steering Committee Recommendation for Endorsement: Y-16 ; N-3

Rationale:
- The measure represents an opportunity to improve the quality of care for patients with schizophrenia and may provide empirical evidence that may be used as a basis for future interventions. The measure was assessed to be important, reliable, valid, useful and feasible.

RECOMMENDATIONS:
- This measure is directly competing with paired measures #1935 Use of any antipsychotic medications (NCQA) and #1936 Continuity of Antipsychotic Medications for Treatment of Schizophrenia (NCQA). The developers have agreed to harmonize the measures #1936 and #1879; the areas for harmonization include: the inclusion criteria for the population starting at 18 years and 25 years, the use of two prescription claims vs. one prescription claim, excluding dementia and including pregnancy in the population. Measure #1935 was withdrawn from consideration as part of the harmonization process.

Public & Member Comment

Comments included:
- CMS expressed support for the Steering Committee’s evaluation of this measure and agreed with the CMS-NCQA proposed strategy for measure harmonization of measures #1879 and #1936.

Developer response:
- NCQA agreed to combine measures #1936 and #1879 into one single, harmonized measure. Measure #1879, stewarded by CMS, now incorporates elements of both of these initially submitted measures, and is currently available for member vote.

CSAC Review
Decision: Approved for endorsement

BOD Review
Decision: Ratified for endorsement

1936 Continuity of Antipsychotic Medications for Treatment of Schizophrenia

NOTE: This measure has been combined with measure #1879 (Adherence to Oral Antipsychotics for Individuals with Schizophrenia). The single harmonized measure (#1879) will be stewarded by CMS. This measure #1936 is therefore considered withdrawn.

Screening Measures

1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

New Measure

Description: The percentage of individuals 25 – 64 years of age with schizophrenia or bipolar disorder, who were prescribed any antipsychotic medication, and who received a diabetes screening during the measurement year.

Numerator Statement: One or more glucose or HbA1c tests performed during the measurement year.

Denominator Statement: Adults age 25 years and older as of December 31 of the measurement year with schizophrenia or bipolar disorder diagnosis and who were prescribed any antipsychotic medication.

Exclusions: Individuals are excluded from the denominator if they have diabetes (during the measurement year or the year prior to the measurement year).

There are two ways to identify individuals with diabetes: 1) pharmacy data or 2) claim/encounter data. Both methods should be used to identify the eligible population, but the individual only needs to be identified by one method to be included in the measure.

Pharmacy data. Individuals who were dispensed insulin or oral hypoglycemics/antihyper-glycemics during the measurement year or year before the measurement year on an ambulatory basis.
# Diabetic Screening for People with Schizophrenia or Bipolar Disorder Who Are Prescribed Antipsychotic Medications

Claim/encounter data. Individuals who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years.

**Codes to identify diabetes:**

<table>
<thead>
<tr>
<th>Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>Type I diabetes</td>
</tr>
<tr>
<td>357.2</td>
<td>Type II diabetes</td>
</tr>
<tr>
<td>362.0</td>
<td>Gestational diabetes</td>
</tr>
<tr>
<td>366.41</td>
<td>Type II diabetes in children</td>
</tr>
<tr>
<td>648.0</td>
<td>Other types of diabetes</td>
</tr>
</tbody>
</table>

**Prescriptions to identify individuals with diabetes:**

- **Alpha-glucosidase inhibitors:** acarbose, miglitol
- **Amylin analogs:** pramlintide
- **Antidiabetic combinations:** glimepiride-pioglitazone, glimepiride-rosiglitazone, glipizide-metformin, glyburide-metformin, metformin-pioglitazone, metformin-rosiglitazone, metformin-sitagliptin, saxagliptin, insulin aspart, insulin aspart-insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, insulin inhalation, insulin isophane beef-pork, insulin isophane human, insulin isophane-insulin regular, insulin lispro, insulin lispro-insulin lispro protamine, insulin regular human, insulin zinc human
- **Meglitinides:** nateglinide, repaglinide
- **Miscellaneous antidiabetic agents:** exenatide, liraglutide, metformin-repaglinide, sitagliptin
- **Sulfonylureas:** acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide
- **Thiazolidinediones:** pioglitazone, rosiglitazone

**Codes to identify visit type:**

- **Outpatient:**
  - UB Revenue: 051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983
- **Nonacute inpatient:**
  - CPT: 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
  - UB Revenue: 0118, 0120-0124, 0129, 0148, 0158, 019x, 0524, 0525, 055x, 066x
- **Acute inpatient:**
  - CPT: 99211-99223, 99231-99233, 99238, 99239, 99251-99255, 99291
  - UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987
- **ED:**
  - CPT: 99281-99285
  - UB Revenue: 045x, 0981

**Adjusted/Stratification:** N/A

**Level of Analysis:** Health Plan/Population: State

**Type of Measure:** Process

**Data Source:** Administrative Claims

**Measure Steward:** National Committee for Quality Assurance

**Steering Committee In-Person April 17-18, 2012**
1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

### 1. Importance to Measure and Report: The measure meets the Importance criteria.
(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

<table>
<thead>
<tr>
<th>Impact Level</th>
<th>H-15</th>
<th>M-4</th>
<th>L-0</th>
<th>I-0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Gap Level</td>
<td>H-15</td>
<td>M-5</td>
<td>L-0</td>
<td>I-0</td>
</tr>
<tr>
<td>Evidence Level</td>
<td>Y-12</td>
<td>N-1</td>
<td>I-7</td>
<td></td>
</tr>
</tbody>
</table>

**Rationale:**
- The Steering Committee agreed the measure addresses a high impact area as individuals with schizophrenia or bipolar disorder have nearly two times the risk for diabetes due to use of antipsychotic medications.
- The Committee was concerned the measure included only schizophrenia and bipolar patients when patients with other diagnoses may be appropriate to include as well.
  - The developer explained the focus is due to the particular risk of the target population, who tend to use the medication for a long time period. On average individuals with schizophrenia and bipolar disease die 25 years earlier than the general population.
- A gap in performance was shown at the state level where the mean value per state was 12.1 percent, and the maximum was 28 percent - individuals with schizophrenia or bipolar are not screened for diabetes as often as they should be.
- The Steering Committee agreed that there was strong evidence to support the measure.
- Committee members expressed an interest in seeing additional evidence to explore whether or not additional diagnoses should be included in the measure, such as body mass index or the presence of metabolic syndrome.

### 2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

| Reliability Level | H-13 | M-0 | L-5 | I-2 |
| Validity Level | H-14 | M-0 | L-5 | I-1 |

**Rationale:**
- The Steering Committee was concerned by the one-year measurement time window, asking whether more periodic screening should be specified.
  - The developer stated that this timeframe was also reviewed by their technical expert panel, which noted the earlier test is often used as a baseline, and then measured again once the individual has been on the medication.
- The Committee agreed the reliability results showed good test/retest capability. Overall, 4 of the 16 states in the test had no change in performance across the quartiles. State performance for this measure correlated at .33 level and accounted for 11 percent of the variance in the 2008 scores.
- The measure demonstrated face validity through the use of a technical expert panel and focus groups. The developers also looked at how the measure related to hospitalization, and found that there was a higher hospitalization rate in the states that had lower screening rates. States that performed at the bottom quartile had approximately 24 percent of their enrollees with schizophrenia hospitalized compared to 18 percent in the states that were in the top quartile of performance for this measure.

### 3. Usability: H-4; M-14; L-1; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**Rationale:**
- The Committee agreed the measure is usable.

### 4. Feasibility:
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Rationale:**
- The Committee agreed the measure was feasible as it relies on administrative claims data.
### 1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

**Steering Committee Recommendation for Endorsement:** Y-13; N-7  
**Rationale:**  
- The measure represents an opportunity to improve the quality of care for patients with schizophrenia and bipolar disorder and may provide empirical evidence which may be used as a basis for future interventions. The measure was assessed to be important, reliable, valid, useful and feasible.  
**Recommendations:**  
- It was recommended that this measure be harmonized with existing NQF endorsed measure #0003 Bipolar Disorder: Assessment for Diabetes (Centers for Quality Assessment and Improvement in Mental Health). The areas for harmonization include level of testing at either the individual or group clinical level vs. the state level, inclusion of those ages 18 and older vs. those 25 and older, the exclusion of patients with diabetes and the use of claim and chart abstractions vs. claim data only.

**Public & Member Comment**  
Comments included:  
- No comments were received for this measure.

**CSAC Review**  
Decision: Approved for continued endorsement

**BOD Review**  
Decision: Ratified for continued endorsement

---

### 1927 Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

**New Measure**  
**Description:** The percentage of individuals 25 – 64 years of age with schizophrenia or bipolar disorder who were prescribed any antipsychotic medication who received a cardiovascular health screening during the measurement year.  
**Numerator Statement:** One or more LDL-C screenings.  
**Denominator Statement:** Adults age 25 and older as of December 31 of the measurement year with a diagnosis of schizophrenia or bipolar disorder who were prescribed any antipsychotic medication.  
**Exclusions:** Individuals are excluded from the denominator if they were discharged alive for a coronary artery bypass graft or percutaneous coronary intervention (these events may occur in the measurement year or year prior to the measurement year), or diagnosed with ischemic vascular disease (this diagnosis must appear both the measurement year and the year before the measurement year), chronic heart failure, or had a prior myocardial infarction (identified in the measurement year or as far back as possible).  
**Adjustment/Stratification:** N/A  
**Level of Analysis:** Health Plan; Population: State  
**Type of Measure:** Process  
**Data Source:** Administrative Claims  
**Measure Steward:** National Committee for Quality Assurance

**Steering Committee In-Person April 17-18, 2012**
Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

1. Importance to Measure and Report: The measure meets the Importance criteria.
(1a. High Impact; 1b. Performance Gap; 1c. Evidence)
1a. Impact: H-7; M-9; L-2; I-1; 1b. Performance Gap: H-8; M-7; L-2; I-2; 1c. Evidence: Y-8, N-3, I-7
Evidence Exception (expert opinion was systematically assessed with agreement that the benefits of the measured process or structure to patients greatly outweigh the potential harms, there is exceptional and compelling reason that the measure should be considered further) Y-10, N-8

Rationale:
- The Steering Committee agreed the measure addresses a high impact area, as individuals with schizophrenia or bipolar disorder are at a greater risk for cardiovascular disease due to lifestyle risk factors, and high non-treatment rates for hyperlipidemia among people with schizophrenia.
- Committee members questioned why cholesterol was the focus rather than tobacco use—the main risk factor for cardiovascular disease in people with mental illness—and obesity.
  - The developer responded that the focus on cholesterol as a risk factor is due to the availability of data from claims.
- The Committee noted that there was overall poor performance with little variation—the 25th percentile was 42 percent, the median was 46 percent, the 75th percentile was 51 percent. The research submitted shows that patients in this population receive cholesterol screening 25 percent less often than the general population, which demonstrates a significant performance gap.
- The Committee noted a lack of evidence regarding the relationship between adherence and desired outcome or improved treatment/diagnosis.
  - The developer stated that there is not a great deal of specific empirical data on patients with schizophrenia and LDL screening for schizophrenics, but there is good evidence of high rates of cardiovascular disease unrecognized in schizophrenics—which demonstrates the need for such a measure.
- The Committee agreed the measure did not meet the evidence criterion, but an exception was warranted as the benefits to patients of screening outweighed potential harm. The measure is a state measure intended to help improve systems, and clearly this population is at higher risk. Screening is a necessary step along the way to improving the health of this population.

2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
2a. Reliability: H-0; M-14; L3-; I-0; 2b. Validity: H-0; M-13; L-3; I-2

Rationale:
- The Committee noted potential difficulties of having individuals with schizophrenia or bipolar fast prior to LDL testing, which is usually done with a panel of other cholesterol tests (HDL, VLDL, LDL) that do require the patient to fast.
- The Steering Committee found the reliability testing in the measure was clear, using data from 16 states of the 22 states. The states that were not included were due to small sample size in the denominator. The reliability testing was based on the stability of performance at the state level and 56 percent of the states found no change between two years. The correlation of the data was moderate at .43.
- The measure’s validity was assessed by establishing face validity from the review done by multi-stakeholder technical advisory groups, state Medicaid health commissioners and focus groups from several organizations. Concurrent validity was based on correlation with other quality indicators related to screening, which was found to be high, along with the ED use for schizophrenia.
  - The measure developer explained that there is a negative relationship between screenings, and there was an assumption that ED use for schizophrenics may be an adverse event. The potential threats to validity were not examined.

3. Usability: H-1; M-12; L-5; I-0
(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)
Rationale:
- The Committee agreed this measure was usable.
### Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

**4. Feasibility:** H-0; M-12; L-6; I-0  
(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Rationale:**
- The Committee agreed moderate feasibility is demonstrated; however, expressed concerns regarding required patient fasting prior to testing and a trend toward co-pays for lab results, the cost of which may discourage patients from being tested.

**Steering Committee Recommendation for Endorsement:** Y-10; N-8

**Rationale:**
- The measure was assessed to be important, reliable, valid, useful and feasible. The Committee invoked the evidence exception for this measure.

**Recommendation:**
- The Steering Committee suggested that capturing obesity, nicotine use in addition to LDL in the measure would strengthen the measure. However, due to the lack of evidence and limited availability of data, the use of LDL screening can be used as a baseline for measuring cardiovascular health for those with schizophrenia and bipolar disorder.

**Public & Member Comment**

**Comments included:**
- No comments were received for this measure.

**CSAC Review**

Decision: Approved for endorsement

**BOD Review**

Decision: Ratified for endorsement

### Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia

**New Measure**

**Description:** The percentage of individuals 25 – 64 years of age with a schizophrenia diagnosis and a diagnosis of cardiovascular disease who received a cardiovascular health monitoring test (LDL-C) during the measurement year.

**Numerator Statement:** One or more LDL-C tests performed during the measurement year.

**Denominator Statement:** Adults 25 years and older as of December 31 of the measurement year with a diagnosis of schizophrenia and cardiovascular disease.

**Exclusions:** N/A

**Adjustment/Stratification:** N/A

**Level of Analysis:** Health Plan, Population: State

**Type of Measure:** Process

**Data Source:** Administrative Claims

**Measure Steward:** National Committee for Quality Assurance

**Steering Committee In-Person April 17-18, 2012**
## Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia

### 1. Importance to Measure and Report: The measure meets the Importance criteria.

**1a. Impact:** H-10; M-7; L-1; I-0

**1b. Performance Gap:** H-6; M-11; L-0; I-1

**1c. Evidence:** Y-15, N-1, I-2

**Rationale:**
- This measure addresses a high impact area.
- This measure was modeled from the general population HEDIS measure monitoring individuals with established cardiovascular disease, the only difference is the denominator population, which is comprised of schizophrenics with cardiovascular disease. The data shows a 26 percent higher rate for monitoring in the general population versus monitoring in the schizophrenic population.

### 2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.

**2a. Reliability:** H-1; M-13; L-4; I-0

**2b. Validity:** H-; M-15; L-2; I-0

**Rationale:**
- The Committee agreed the reliability of the measure was demonstrated by the testing.
- The measure’s validity was assessed by establishing face validity from the review done by multi-stakeholder technical advisory groups, state Medicaid health commissioners and focus groups from several organizations. Concurrent validity was based on correlation with other quality indicators related to monitoring.
- The Committee noted the same concerns with usability as they did in #1927, noting potential difficulties of individuals with schizophrenia or bipolar fasting prior to LDL testing, which is usually done with a panel of other cholesterol tests (HDL, VLDL, LDL) that do require the patient to fast.

### 3. Usability: H-2; M-12; L-4; I-0

**Rationale:**
- The Steering Committee agreed this measure was usable.

### 4. Feasibility: H-1; M-12; L-5; I-0

**Rationale:**
- The Committee agreed feasibility is demonstrated; however, expressed concerns regarding required patient fasting prior to testing and a trend toward co-pays for lab results, the cost of which may discourage patients from being tested.

**Steering Committee Recommendation for Endorsement:** Y-16; N-2

**Rationale:**
- The measure was assessed to be important, reliable, valid, useful and feasible.

**Public & Member Comment**

**Comments included:**
- No comments were received for this measure.

**CSAC Review**

Decision: Approved for endorsement

**BOD Review**

Decision: Ratified for endorsement
<table>
<thead>
<tr>
<th>1934 Diabetes monitoring for people with diabetes and schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description:</strong> The percentage of individuals 25 – 64 years of age with schizophrenia and diabetes who received diabetes monitoring as specified by an HbA1c test and LDL-C test during the measurement year.</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> One or more HbA1c tests and one or more LDL-C tests performed during the measurement year.</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> Adults age 25 years and older as of December 31 of the measurement year with a schizophrenia and diabetes diagnosis.</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> N/A</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong> N/A</td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Population : State</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative Claims</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> National Committee for Quality Assurance</td>
</tr>
</tbody>
</table>

**Steering Committee In-Person April 17-18, 2012**

1. **Importance to Measure and Report:** The measure meets the Importance criteria.
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   1a. **Impact:** H-10; M-6; L-; I-; 1b. **Performance Gap:** H-8; M-8; L-0; I-0; 1c. **Evidence:** Y-13, N-1, I-2

**Rationale:**
- This measure addresses a high impact area as studies cite that one-third of individuals with both diabetes and schizophrenia do not receive treatment.
- This measure was based on the HEDIS measure that focuses on monitoring of individuals with a diagnosis of diabetes but focuses on a subset of patients who also have a diagnosis of schizophrenia. The performance rate found within the diabetes measure was 70 to 80 percent, while the rate of the subset of patients who also have schizophrenia was 50 percent.
- The Committee discussed the possibility of this measure being included as a strata within the existing NQF-endorsed measure #0057 Diabetes: Hemoglobin A1c testing (NCQA). A key difference between the two measures is the diabetes measure includes individuals 18 to 75 years of age and the measure before the Committee includes those 25 to 64 years of age. The developer is willing to reconcile the measures.

2. **Scientific Acceptability of Measure Properties:** The measure meets the Scientific Acceptability criteria.
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   2a. **Reliability:** H-1; M-15; L-1; I-0; 2b. **Validity:** H-1; M-15; L-1; I-0

**Rationale:**
- The Committee agreed reliability of the measure was demonstrated.
- Face validity was assessed by multi-stakeholder technical advisory groups, state Medicaid health commissioners and focus groups from several organizations. Concurrent validity was based on high correlation with other quality indicators related to monitoring.

3. **Usability:** H-0; M-17; L-0; I-0
   *(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)*

**Rationale:**
- The Steering Committee agreed this measure was usable.

4. **Feasibility:** H-1; M-15; L-1; I-0
   *(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)*

**Rationale:**
- The Committee agreed feasibility is demonstrated; however, expressed concerns regarding required patient fasting prior to testing and a trend toward co-pays for lab results, the cost of which may discourage patients from being tested.
**1934 Diabetes monitoring for people with diabetes and schizophrenia**

**Steering Committee Recommendation for Endorsement: Y-17; N-0**

**Rationale:**
- The measure was assessed to be important, reliable, valid, useful and feasible.

**RECOMMENDATIONS:**
- The Steering Committee discussed the possibility of this measure being included as a strata within the existing NQF-endorsed measure #0057 Diabetes: Hemoglobin A1c testing (NCQA) and #0063 Diabetes: Lipid profile (NCQA).
  - NCQA agreed to incorporate the new measure as a subset or target population within the more broadly defined NQF endorsed measures (#0057 and #0063) following the member voting period and CSAC/Board review.

**Public & Member Comment**

**Comments included:**
- No comments were received for this measure.

**CSAC Review**
- Decision: Approved for endorsement

**BOD Review**
- Decision: Ratified for endorsement
### 1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)

**New Measure**

**Description:** The percentage of discharges for individuals 25 – 64 years of age who were hospitalized for treatment of schizophrenia and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported.

- The percentage of individuals who received follow-up within 30 days of discharge
- The percentage of individuals who received follow-up within 7 days of discharge

**Numerator Statement:** 30-Day Follow-Up: An outpatient visit, intensive outpatient encounter or partial hospitalization (Table–C) with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge. 7-Day Follow-Up: An outpatient visit, intensive outpatient encounter or partial hospitalization (Table–C) with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.

**Denominator Statement:** Adults 25 – 64 years of age of December 31 of the measurement year Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal schizophrenia diagnosis.

**Exclusions:** Schizophrenia readmission or direct transfer: If the discharge is followed by readmission or direct transfer to an acute facility for a schizophrenia diagnosis within the 30-day follow up period, count only the readmission discharge or the discharge from the facility to which the member was transferred. Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year. Exclude discharges followed by readmission or direct transfer to a non-acute facility for a schizophrenia diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Non-mental health readmission or direct transfer: Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or non-acute facility for a non-mental health principal diagnosis. These discharges are excluded from the measure because re-hospitalization or transfer may prevent an outpatient follow-up visit from taking place.

**Adjustment/Stratification:** N/A

**Level of Analysis:** Population: State

**Type of Measure:** Process

**Data Source:** Administrative claims

**Measure Steward:** National Committee for Quality Assurance

#### 1. Importance to Measure and Report: The measure meets the Importance criteria.

(1a. High Impact; 1b. Performance Gap; 1c. Evidence)

1a. Impact: H-6; M-7; L-1; I-0

1b. Performance Gap: H-10; M-4; L-0; I-0

1c. Evidence: Y-13, N-1, I-0

**Rationale:**

- The Committee believes this measure addresses a high impact area, as individuals with schizophrenia have high cost healthcare expenditures and typically lack follow-up post hospitalization.
- This measure demonstrates a high performance gap area, as evidence shows that follow-up is a significant problem for individuals with schizophrenia compared to the general population.
2. Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria. 
(2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)

2a. Reliability: H-8; M-6; L-0; I-0; 2b. Validity: H-5; M-8; L-0; I-0

Rationale:
- The Committee agreed the measure demonstrated reliability and validity:
  - The developer conducted an analysis of test-retest reliability for state results to assess the reliability of state-level performance. Stability over time was tested by computing quartiles of performance based on the state distribution for each measure and assigning each state a score reflecting performance relative to other states in the distribution during the measurement years 2007 and 2008. The developer also reported Pearson correlations measuring the association between 2007 and 2008 measure performance for the 16 states with data.
  - The measure showed good to modest test-retest reliability with no change in performance quartile between 2007 and 2008. Performance was correlated at r=0.173 and r=.202, respectively, for 7- and 30-day follow-up, indicating that 2007 performance on this measure accounted for 3% and 4%, respectively of the variance in 2008 scores.
  - The developer demonstrated face validity, as the Technical Advisory Group overseeing development of the measure and focus groups deemed the measures important, usable and feasible to collect. Concurrent validity, as beneficiaries in the lowest performing states had higher rates of schizophrenia related hospitalization, comparing 7 and 30 day rates; and concurrent and discriminant validity, as the 7-day follow-up measure was correlated with 30-day follow-up measure (r=.495). Additionally, the 7- and 30-day follow-up measure was correlated with high antipsychotic continuity (r=.103 and r=.153, respectively).

3. Usability: H-3; M-10; L-0; I-1

(Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

Rationale:
- The measure is easily understood and was rated as meaningful, understandable, and useful for public reporting by participants in focus groups. Those groups included representatives from State Medicaid programs, for whom the measure is intended to be used for public reporting, and quality improvement and benchmarking.

4. Feasibility: H-7; M-6; L-0; I-1

(4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/unintended consequences identified 4d. Data collection strategy can be implemented)

Rationale:
- Performance data are captured in claims/encounter systems.
- The Committee noted there may be difficulty following up with individuals due to socioeconomic issues such as homelessness or living in group housing, which is difficult to capture in administrative data.
- The Committee noted poverty, crime and living in unsafe neighborhoods all play a role in the difficulty to ensure adequate follow up with these patients.

Steering Committee Recommendation for Endorsement: Y-13; N-1

Rationale:
- This is an important area for measurement, as there are few measures of quality related to follow up and transition of care over time particularly in this population.

Recommendation:
- The Steering Committee discussed the possibility of including this measure as strata within the existing NQF-endorsed measure #0576 Follow-Up After Hospitalization for Mental Illness (NCQA).
  - NCQA agreed to incorporate the new measure #1937 as a subset or target population within the more broadly defined measure #0576 following the member voting period and CSAC/Board reviews.

Public & Member Comment

Comments included:
- No comments were received for this measure.
Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) CSAC Review Decision: Approved for endorsement

Follow-Up After Hospitalization for Mental Illness Maintenance Measure Description: This measure assesses the percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported.

Rate 1. The percentage of members who received follow-up within 30 days of discharge
Rate 2. The percentage of members who received follow-up within 7 days of discharge.

Numerator Statement:
Rate 1: An outpatient visit, intensive outpatient encounter or partial hospitalization with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.
Rate 2: An outpatient visit, intensive outpatient encounter or partial hospitalization with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.

Denominator Statement:
Members 6 years and older as of the date of discharge who were discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal mental health diagnosis on or between January 1 and December 1 of the measurement year. The denominator for this measure is based on discharges, not members. Include all discharges for members who have more than one discharge on or between January 1 and December 1 of the measurement year. Mental health readmission or direct transfer: If the discharge is followed by readmission or direct transfer to an acute facility for a mental health principal diagnosis (within the 30-day follow-up period), count only the readmission discharge or the discharge from the facility to which the member was transferred. Although re-hospitalization might not be for a selected mental health disorder, it is probably for a related condition. Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year. Exclude discharges followed by readmission or direct transfer to a non-acute facility for a mental health principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because re-hospitalization or transfer may prevent an outpatient follow-up visit from taking place. Refer to Table FUH-B for codes to identify non-acute care. Non-mental health readmission or direct transfer: Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or non-acute facility for a non-mental health principal diagnosis. This includes an ICD-9-CM Diagnosis code or DRG code other than those in Tables MPT-A and MPT-B. These discharges are excluded from the measure because re-hospitalization or transfer may prevent an outpatient follow-up visit from taking place.

Exclusions: Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year. Exclude discharges followed by readmission or direct transfer to a non-acute facility for any mental health principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Refer for codes to identify non-acute care. Non-mental health readmission or direct transfer: Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or non-acute facility for a non-mental health principal diagnosis. These discharges are excluded from the measure because re-hospitalization or transfer may prevent an outpatient follow-up visit from taking place.

Adjustment/Stratification: N/A


Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data: Electronic Health Record

Measure Steward: National Committee for Quality Assurance
### 0576 Follow-Up After Hospitalization for Mental Illness

**Steering Committee In-Person April 17-18, 2012**

1. **Importance to Measure and Report: The measure meets the Importance criteria.**  
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   
   **1a. Impact:** H-6; M-7; L-1; I-0  
   **1b. Performance Gap:** H-10; M-4; L-0; I-0  
   **1c. Evidence:** Y-13, N-1, I-0

**Rationale:**
- The Committee believes this measure addresses a high impact area, as individuals with schizophrenia have high cost healthcare expenditures and typically lack follow-up post hospitalization.
- The measure has been reported in HEDIS for 10 years, the average performance rate at seven days is 45 to 50 percent. Over time, the rate has improved but the Medicaid rates remain very low. At 30 days the rate is closer to 70 percent.
- The Committee agreed the evidence presented demonstrates that outcomes are poorer when follow up does not occur.

2. **Scientific Acceptability of Measure Properties: The measure meets the Scientific Acceptability criteria.**  
   (2a. Reliability – precise specifications, testing; 2b. Validity – testing, threats to validity)
   
   **2a. Reliability:** H-8; M-6; L-0; I-0  
   **2b. Validity:** H-5; M-8; L-0; I-0

**Rationale:**
- The Steering Committee agreed reliability and validity of the measure was demonstrated.
  - The developer used a beta-binomial approach to estimate reliability using a 0.0 to 1.0 reliability score, where a minimum reliability score of 0.7 is used to indicate sufficient signal strength to discriminate performance between accountable entities. The results for the percentage of members who received follow-up within 30 days of discharge were 0.949 or better for Commercial, Medicaid and Medicare populations, and the results for members who received follow-up within 7 days of discharge were 0.95 or better for the three populations.
  - The measure was written, field-tested, and presented to the CPM and incorporated into HEDIS in 1994.

3. **Usability:** H-3; M-10; L-0; I-1  
   (Meaningful, understandable, and useful to the intended audiences for 3a. Public Reporting and 3b. Quality Improvement)

**Rationale:**
- The measure is easily understood and currently in use for public reporting, regulatory accreditation programs, quality improvement, benchmarking, external benchmarking over multiple organizations and then internal quality improvement within a specific organization.
- The Committee noted that if the measure received continued endorsement, the developer should review its usefulness for additional populations.

4. **Feasibility:** H-7; M-6; L-0; I-1  
   (4a. Clinical data generated during care process; 4b. Electronic data; 4c. Susceptibility to inaccuracies/ unintended consequences identified 4d. Data collection strategy can be implemented)

**Rationale:**
- There may be difficulty following up with individuals due to socioeconomic issues such as homelessness or living in group housing, which is difficult to capture in administrative data.
- The Committee noted poverty, crime and living in unsafe neighborhoods all play a role in the difficulty to ensure adequate follow up with these patients.
<table>
<thead>
<tr>
<th>0576 Follow-Up After Hospitalization for Mental Illness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steering Committee Recommendation for Endorsement:</strong> Y-13; N-1</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
</tr>
<tr>
<td>• There are few measures of quality related to follow up and transition of care over time. This measure has been in use over 10 years and addresses a population for which follow-up is critical.</td>
</tr>
<tr>
<td><strong>Recommendation:</strong></td>
</tr>
</tbody>
</table>
| • The Steering Committee discussed the possibility of including #1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA) as strata for the schizophrenic population within this measure.  
  o NCQA agreed to incorporate the new measure #1937 as a subset or target population within the more broadly defined measure #0576 following the member voting period and CSAC/Board reviews.  
• Committee members suggested highly vulnerable groups who receive disparate care, including the fragile elderly, should be included in the measure, and extending the target age beyond 64 should be considered. |
| **Public & Member Comment** |
| **Comments included:** |
| • No comments were received for this measure. |
| **CSAC Review** |
| Decision: Approved for continued endorsement |
| **BOD Review** |
| Decision: Ratified for continued endorsement |
Measures Not Endorsed

Emergency Department Utilization

<table>
<thead>
<tr>
<th>1938 Emergency department utilization for mental health conditions by people with schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description:</strong> The percentage of individuals 25 – 64 years of age with a schizophrenia diagnosis who had an emergency department admission for mental health.</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> An admission to the ED with a mental health diagnosis.</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> Adults 25 – 64 years of age as of December 31 of the measurement year with a schizophrenia diagnosis.</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> N/A</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong> N/A</td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Population: State, Health Plan</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative claims</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> National Committee for Quality Assurance</td>
</tr>
</tbody>
</table>

Steering Committee In-Person April 17-18, 2012

1. Importance to Measure and Report: **The measure did not meet the Importance criteria.**
   (1a. High Impact; 1b. Performance Gap; 1c. Evidence)
   1a. Impact: H-0; M-1; L-4; I-11; b. Performance Gap: H-; M-; L-; I-; 1c. Evidence: Y-, N-, I-
   **Rationale:**
   - The measure seeks to demonstrate the rate at which patients with schizophrenia utilize the emergency department; however, it is unknown whether or not the visit has a positive or negative affect on the outcome.
   - The evidence appears contradictory because the relative rates of emergency department utilization may be reflective of either inappropriate use or demonstrate barriers to care. The increased use of services may be driven by either increased severity of mental illness and medical disorders.
     o The measure developer stated that the purpose of the measure was to use the rates to understand how to potentially avoid hospitalizations.
   - The Steering Committee believes this measure may be more appropriate as a measure used to gauge disengagement rather than using this as an accountability measure for comparison across states.
   - This measure may have the unintended consequence of showing overutilization of emergency departments by schizophrenics and could possibly negatively impact reimbursement if they are deemed unnecessary. This may discourage patients with a diagnosis of schizophrenia from seeking care.
   - Because the measure did not pass the impact subcriteria, the remaining subcriteria for importance were not evaluated.

Steering Committee Recommendation for Endorsement: Y-; N-
   **Rationale:**
   - The measure did not pass the Importance to Measure and Report criteria.

**RECOMMENDATIONS:**
- A measure related to follow-up after an emergency department visit might better address the concerns this measure attempts to resolve.

Public & Member Comment
   **Comments included:**
   - No comments were received for this measure.
Measures Deferred

Endorsement decisions for eight tobacco and alcohol related Joint Commission measures have been deferred to the second phase of the Behavioral Health project. Seven of the measures passed the Importance to Measure and Report criterion, but the consensus of the Committee was that scientific acceptability was not met at this time. The Joint Commission has indicated that they are continuing to test the measures and will provide additional test data to the Steering Committee on the revised measures by late 2012 or early 2013 so that the measures may complete the endorsement process. The measures have been deferred for further consideration until that time.

Another measure – 1651:TOB-1 Tobacco Use Screening – was recommended by a close vote, but the Committee did articulate concerns that the measure did not demonstrate adequate reliability. The NQF membership and the CSAC did not reach clear consensus on the measure, also concerned with the reliability based on testing presented. Accordingly, after consultation with NQF, the Joint Commission decided to defer this measure to be considered in the second phase of the Behavioral Health project, along with the other seven measures that had already been deferred.

The deferred measures include:

- #1651 TOB-1 Tobacco Use Screening
- #1654 TOB-2 Tobacco Use Treatment Provided or Offered (and the subset measure TOB-2a Tobacco Use Treatment)
- #1656 TOB-3 Tobacco Use Treatment Provided or Offered at Discharge and the subset measure TOB-3a Tobacco Use Treatment at Discharge
- #1657 TOB-4 Tobacco Use: Assessing Status after Discharge
- #1661 SUB-1 Alcohol Use Screening
- #1663 SUB-2 Alcohol Use Brief Intervention Provided or Offered and SUB-2a Alcohol Use Brief Intervention
- #1664 SUB-3 Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge and SUB-3a Alcohol and Other Drug Use Disorder Treatment at Discharge
- #1665 SUB-4 Alcohol and Drug Use: Assessing Status After Discharge

Withdrawn From Consideration

Measure #1926 Cervical cancer screening for women with schizophrenia (NCQA) was withdrawn prior to Steering Committee review. In the time between submission and review, the U.S. Preventative Services Task Force (USPSTF) issued new recommendations regarding cervical cancer screening for women. The NCQA is currently reevaluating the overall cervical cancer screening measure #0032 Cervical Cancer Screening (NCQA), as well as #1926 Cervical cancer screening for women with schizophrenia (NCQA), which focuses specifically on women with schizophrenia. NCQA plans to resubmit the measure after it has been reevaluated to be consistent with the updated USPSTF guidelines.

The Steering Committee evaluated three similar measures related to adherence to antipsychotic medication for patients with schizophrenia (#1879 and measure pair #1935 and #1936), and agreed it was preferable to recommend a single, harmonized measure rather than multiple, overlapping measures.
As a result of the developers’ work, measures #1935 and #1936 have been withdrawn from consideration. Measures #1936 and #1879 have been combined into one harmonized measure, #1879 Adherence to Antipsychotic Medications for Individuals with Schizophrenia, stewarded by CMS.

Endnotes


4 Ibid.

5 Ibid.
## Appendix A – Measure Specifications

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>0004 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment</td>
<td>37</td>
</tr>
<tr>
<td>0027 Medical Assistance With Smoking and Tobacco Use Cessation</td>
<td>40</td>
</tr>
<tr>
<td>0028 Preventive Care &amp; Screening: Tobacco Use: Screening &amp; Cessation Intervention</td>
<td>43</td>
</tr>
<tr>
<td>0576 Follow-Up After Hospitalization for Mental Illness</td>
<td>46</td>
</tr>
<tr>
<td>1879 Adherence to Antipsychotics for Individuals with Schizophrenia</td>
<td>48</td>
</tr>
<tr>
<td>1927 Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</td>
<td>53</td>
</tr>
<tr>
<td>1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</td>
<td>55</td>
</tr>
<tr>
<td>1933 Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia</td>
<td>58</td>
</tr>
<tr>
<td>1934 Diabetes monitoring for people with diabetes and schizophrenia</td>
<td>59</td>
</tr>
<tr>
<td>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</td>
<td>60</td>
</tr>
<tr>
<td><strong>0004 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>Status</strong></td>
<td>Maintenance, Original Endorsement: Aug 10, 2009</td>
</tr>
<tr>
<td><strong>Steward</strong></td>
<td>National Committee for Quality Assurance</td>
</tr>
</tbody>
</table>
| **Description** | The percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) dependence who received the following.  
  a. Initiation of AOD Treatment. The percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis.  
  b. Engagement of AOD Treatment. The percentage of members who initiated treatment and who had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit. |
| **Type** | Process |
| **Data Source** | Administrative claims, Electronic Clinical Data: Electronic Health Record, Paper Records  
  NCQA collects HEDIS data directly from Health Management Organizations and Preferred Provider Organizations via a data submission portal - the Interactive Data Submission System (IDSS).  
  URL http://www.ncqa.org/tabid/370/default.aspx |
| **Level** | Health Plan, Integrated Delivery System, Population: County or City, Population: National, Population: Regional |
| **Setting** | Ambulatory Care: Clinic/Urgent Care, Ambulatory Care: Clinician Office, Behavioral Health/Psychiatric: Outpatient, Emergency Medical Services/Ambulance, Hospital/Acute Care Facility |
| **Numerator Statement** | a) Initiation of AOD Dependence Treatment: Initiation of AOD treatment through an inpatient admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of diagnosis.  
  • If the Index Episode was an inpatient discharge, the inpatient stay is considered initiation of treatment and the member is compliant  
  • If the Index Episode was an outpatient, intensive outpatient, partial hospitalization, detoxification or ED visit, the member must have an inpatient admission, outpatient visit, intensive outpatient encounter or partial hospitalization (Table IET-B) with an AOD diagnosis (Table IET-A) within 14 days of the IESD (inclusive)  
  – If the initiation encounter is an inpatient admission, the admission date (not the discharge date) must be within 14 days of the IESD (inclusive)  
  • Do not count Index Episodes that include detoxification codes (including inpatient detoxification) as being initiation of treatment  
  b) Engagement of AOD Treatment:  
  Initiation of AOD treatment and two or more inpatient admissions, outpatient visits, intensive outpatient encounters or partial hospitalizations (Table IET-B) with any AOD diagnosis (Table IET-A) within 30 days after the date of the Initiation encounter (inclusive). Multiple engagement visits may occur on the same day, but they must be with different providers in order to be counted.  
  For members who initiated treatment via an inpatient stay, use the discharge date as the start of the 30-day engagement period.  
  • If the engagement encounter is an inpatient admission, the admission date (not the discharge date) must be within 30 days of the Initiation encounter (inclusive).  
  • Do not count engagement encounters that include detoxification codes (including inpatient detoxification) |
### Numerator Details

**Time Window:** 44 days after diagnosis.

**Table IET-A: Codes to Identify AOD Dependence**

ICD-9-CM Diagnosis

- 291-292
- 303.00-303.02
- 304.00-304.02
- 304.10-304.12
- 304.20-304.22
- 304.30-304.32
- 304.40-304.42
- 304.50-304.52
- 304.60-304.62
- 304.70-304.72
- 304.80-304.82
- 304.90-304.92
- 305.00-305.02
- 305.20-305.22
- 305.30-305.32
- 305.40-305.42
- 305.50-305.52
- 305.60-305.62
- 305.70-305.72
- 305.80-305.82
- 305.90-305.92
- 535.3
- 571.1

**Table IET-B: Codes to Identify Outpatient, Intensive Outpatient and Partial Hospitalization Visits**

- UB Revenue: 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0907, 0911-0917, 0919, 0944, 0945, 0982, 0983
- CPT: 90801, 90802, 90845, 90847, 90849, 90853, 90857, 90862, 90875, 90876
- WITH POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 33, 49, 50, 52, 53, 57, 71, 72
- CPT: 90816-90819, 90821-90824, 90826-90829, 99221-99223, 99231-99233, 99238, 99239, 99251-99255
- WITH POS: 52, 53

**Table IET-C: Codes to Identify Detoxification Visits**

- HCPCS: H0008-H0014
- ICD-9-CM Procedure: 94.62, 94.65, 94.68
- UB Revenue: 0116, 0126, 0136, 0146, 0156

**Table IET-D: Codes to Identify ED Visits**

- CPT: 99281-99285
- UB Revenue: 045x, 0981

**Table IET-E: Codes to Identify AOD Procedures**

- ICD-9-CM Procedure: 94.61, 94.63, 94.64, 94.66, 94.67, 94.69

### Denominator Statement

Members age 13 years of age and older with a medical and chemical dependency benefit who were diagnosed with a new episode of alcohol and drug dependency (AOD) during the intake period of January 1-November 15 of the measurement year. The Intake Period is used to capture new episodes of AOD.
## 0004 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment

### Denominator Details

**Time Window:** The Intake Period, which is January 1 through November 15 of the measurement year.

For commercial, Medicaid and Medicare product lines, and for members with a medical and chemical dependency benefit who meet the continuous enrollment criteria of 60 days prior to the index episode start date through 44 days after the index episode start date.

Identify the Index Episode. Identify all members in the specified age range who during the Intake Period had one of the following.

- An outpatient visit, intensive outpatient encounter or partial hospitalization (Table IET-B) with a diagnosis of AOD (Table IET-A)
- A detoxification visit (Table IET-C)
- An ED visit (Table IET-D) with a diagnosis of AOD (Table IET-A)
- An inpatient discharge with a diagnosis of AOD as identified by either of the following.
  - An inpatient facility code in conjunction with a diagnosis of AOD (IET-A)
  - An inpatient facility code in conjunction with an AOD procedure code (IET-E)

For members with more than one episode of AOD, use the first episode.

For members whose first episode was an ED visit that resulted in an inpatient stay, use the inpatient discharge.

Select the IESD.

Test for Negative Diagnosis History and calculate continuous enrollment.

Members must be continuously enrolled without any gaps 60 days (2 months) before the IESD through 44 days after the IESD.

### Exclusions

Exclude members who had a claim/encounter with a diagnosis of AOD (Table IET-A) during the 60 days (2 months) before the IESD.

For an inpatient IESD, use the admission date to determine the Negative Diagnosis History.

For an ED visit that results in an inpatient stay, use the ED date of service to determine the Negative Diagnosis History.

Exclude from the denominator members whose initiation encounter is an inpatient stay with a discharge date after December 1 of the measurement year.

### Exclusion Details

Exclude members who had a claim/encounter with a diagnosis of AOD (Table IET-A) during the 60 days (2 months) before the IESD.

**Table IET-A: Codes to Identify AOD Dependence**

<table>
<thead>
<tr>
<th>ICD-9-CM Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>291-292, 303.00-303.02, 303.90-303.92, 304.00-304.02, 304.10-304.12, 304.20-304.22, 304.30-304.32, 304.40-304.42, 304.50-304.52, 304.60-304.62, 304.70-304.72, 304.80-304.82, 304.90-304.92, 305.00-305.02, 305.20-305.22, 305.30-305.32, 305.40-305.42, 305.50-305.52, 305.60-305.62, 305.70-305.72, 305.80-305.82, 305.90-305.92, 535.3, 571.1</td>
</tr>
</tbody>
</table>

### Risk Adjustment

No risk adjustment or risk stratification

N/A

### Stratification

N/A

### Type Score

Rate/proportion better quality = higher score

### Algorithm

Step 1. Determine the eligible population. The eligible population is all members who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.

Step 2. Search administrative systems to identify numerator events for all members in the eligible population.

Step 3. Calculate the rate.
<table>
<thead>
<tr>
<th>0004 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Copyright/Disclaimer</strong> © 2012 by the National Committee for Quality Assurance</td>
</tr>
<tr>
<td>1100 13th Street, NW, Suite 1000</td>
</tr>
<tr>
<td>Washington, DC 20005</td>
</tr>
<tr>
<td>These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.</td>
</tr>
<tr>
<td>THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>0027 Medical Assistance With Smoking and Tobacco Use Cessation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong> Maintenance, Original Endorsement: 10-Aug-09</td>
</tr>
<tr>
<td><strong>Steward</strong> National Committee for Quality Assurance</td>
</tr>
<tr>
<td><strong>Description</strong> Assesses different facets of providing medical assistance with smoking and tobacco use cessation:</td>
</tr>
<tr>
<td>Advising Smokers and Tobacco Users to Quit: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who received advice to quit during the measurement year.</td>
</tr>
<tr>
<td>Discussing Cessation Medications: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were recommended cessation medications during the measurement year.</td>
</tr>
<tr>
<td>Discussing Cessation Strategies: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were provided smoking cessation methods or strategies during the measurement year.</td>
</tr>
<tr>
<td><strong>Type</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source</strong> Patient Reported Data/Survey CAHPS Health Plan Survey 4.0H, Adult Version; Medicare CAHPS</td>
</tr>
<tr>
<td>URL <a href="https://www.cahps.ahrq.gov/default.asp">https://www.cahps.ahrq.gov/default.asp</a></td>
</tr>
<tr>
<td><strong>Level</strong> Health Plan</td>
</tr>
<tr>
<td><strong>Setting</strong> Ambulatory Care: Clinician Office, Other In addition to clinician visits, some respondents may recall other contacts with clinicians or health plans (e.g. smoking cessation classes)</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong> Component 1: Advising Smokers and Tobacco Users to Quit (ASTQ)</td>
</tr>
<tr>
<td>Received advice to quit smoking</td>
</tr>
<tr>
<td>Component 2: Discussing Cessation Medications (DSCM)</td>
</tr>
<tr>
<td>Received discussion/recommendations on smoking cessation medications</td>
</tr>
<tr>
<td>Component 3: Discussing Cessation Strategies (DSCS)</td>
</tr>
<tr>
<td>Received discussion/recommendations on smoking cessation methods and strategies</td>
</tr>
</tbody>
</table>
| **Numerator Details** | **Time Window:** This measure is collected annually via patient survey using the CAHPS 4.0H, Adult Version (Commercial and Medicaid Product lines) and Medicare CAHPS survey.  
For Commercial and Medicaid product lines:  
Advising Smokers and Tobacco Users to Quit:  
The number of members in the denominator who indicated that they received advice to quit from a doctor or other health provider. CAHPS question:  
Q46. In the last 12 months, how often were you advised to quit smoking or using tobacco by a doctor or other health provider in your plan?  
Discussing Smoking Cessation Medications  
The number of members in the denominator who indicated that medication to assist with quitting smoking was recommended or discussed. CAHPS question:  
Q47. In the last 12 months, how often was medication recommended or discussed by a doctor or health provider to assist you with quitting smoking or using tobacco? Examples of medication are: nicotine gum, patch, nasal spray, inhaler, or prescription medication.  
Discussing Cessation Strategies  
The number of members in the denominator who indicated that their doctor or health provider recommended or discussed methods and strategies other than medication to assist with quitting smoking.  
CAHPS question:  
Q48. In the last 12 months, how often did your doctor or health provider discuss or provide methods and strategies other than medication to assist you with quitting smoking or using tobacco? Examples of methods and strategies are: telephone helping, individual group counseling, or cessation program.  
Response Options for all questions:  
Never, Sometimes, Usually, Always  
For the Medicare Product line:  
Advising Smokers or Tobacco Users to Quit  
The number of members in the denominator who indicated that they received advice to quit from a doctor or other health provider  
CAHPS question:  
Q58. In the last 6 months, on how many visits were you advised to quit smoking or using tobacco by a doctor or other health provider in your plan?  
Response Options for all questions:  
Never, Sometimes, Usually, Always |
| **Denominator Statement** | Patients 18 years and older who responded to the survey and indicated that they were current smokers or tobacco users |
### 0027 Medical Assistance With Smoking and Tobacco Use Cessation

<table>
<thead>
<tr>
<th><strong>Denominator Details</strong></th>
<th><strong>Time Window:</strong> 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For the Commercial and Medicaid Product Lines:</strong> Number of members who responded to the survey and indicated that they were current tobacco users and supplied an answer to the next survey question on advice to quit. Member response choices must be as follows to be included in the denominator: Do you now smoke cigarettes or use tobacco every day, some days, or not at all? Response Choices: Every day, Some days, Not at all, Don’t know Response must = Every day OR Some days In the last 12 months, how often were you advised to quit smoking or using tobacco by a doctor or other health provider in your plan? Response Choices: Never, Sometimes, Usually, Always Response must = Never OR Sometimes OR Usually OR Always</td>
<td></td>
</tr>
<tr>
<td><strong>For the Medicare Product Lines:</strong> The number of members who responded to the survey and indicated that they were current smokers or tobacco users and had one or more visits during the measurement year, and supplied an answer to the next survey question on advice to quit. The member responses must be as follows to be included in the denominator: Do you now smoke cigarettes or use tobacco every day, some days, or not at all? Response choices: Never, Sometimes, Usually, Always Response must = Every day or Some days In the last 6 months, on how many visits were you advised to quit smoking or using tobacco by a doctor or other health provider in your plan? Response choices: Never, Sometimes, Usually, Always Response must = Never OR Sometimes OR Usually OR Always The Medicare results for the Advising Smokers and Tobacco Users to Quit Rate requires a minimum denominator of at least 30 responses.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Exclusions</strong></th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion Details</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Type Score</strong></td>
<td>Rate/proportion better quality = higher score</td>
</tr>
<tr>
<td><strong>Algorithm</strong></td>
<td>For the commercial and Medicaid product lines, rolling averages are calculated using the formula Rate = (Year 1 Numerator + Year 2 Numerator)/(Year 1 Denominator + Year 2 Denominator) If the denominator is less than 100, NCQA assigns a measure result of NA If the denominator is 100 or more, NCQA calculates the result. If the health plan did not report results for the current year (Year 2), NCQA assigns a measure result of NA If the health plan did not report results in the prior year (Year 1), but reports results for the current year and achieves a denominator of 100 or more, NCQA calculates a rate; if the denominator is less than 100, NCQA assigns a measure result of N/A. For the Medicare product line, this is collected by the Centers for Medicare &amp; Medicaid Services through the Medicare CAHPS Survey. This is collected on an annual basis. Rate = Year 1 Numerator / Year 2 Denominator</td>
</tr>
</tbody>
</table>
### 0027 Medical Assistance With Smoking and Tobacco Use Cessation

**Copyright/Disclaimer**
© 2012 by the National Committee for Quality Assurance
1100 13th Street, NW, Suite 1000
Washington, DC 20005

### 0028 Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention

**Status**
Maintenance, Original Endorsement: 10-Aug-09

**Steward**
American Medical Association - convened Physician Consortium for Performance Improvement (AMA-convened PCPI)

**Other organizations**: The measure was developed by a multi-disciplinary, cross-speciality work group representing all key stakeholders and including representation from the following specialties, most of whom were sponsored by their medical specialty society: family medicine, internal medicine, geriatric medicine, gastroenterology, general surgery, colon & rectal surgery, infectious disease, radiology, cardiology, obstetrics & gynecology, emergency medicine, preventive medicine, occupational medicine, nursing, psychology, occupational therapy, chiropractics, dietetics, optometry.

**Description**
Percentage of patients aged 18 years and older who were screened for tobacco use at least once during the two-year measurement period AND who received tobacco cessation counseling intervention if identified as a tobacco user

**Type**
Process

**Data Source**
Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Pharmacy, Paper Medical Records Not applicable.
Attachment NQF_Submission_Tobacco.pdf

**Level**
Clinician : Group/Practice, Clinician : Individual, Clinician : Team

**Setting**
Ambulatory Care : Clinician Office/Clinic, Behavioral Health/Psychiatric : Outpatient, Other Occupational Therapy Evaluation

**Numerator Statement**
Patients who were screened for tobacco use* at least once during the two-year measurement period AND who received tobacco cessation counseling intervention** if identified as a tobacco user

- *Includes use of any type of tobacco
- ** Cessation counseling intervention includes brief counseling (3 minutes or less), and/or pharmacotherapy

**Numerator Details**
Time Window: Once during measurement period
For Electronic Health Record specifications - See attached for PCPI eSpecification; HQMF eMeasure under development
For Claims/Administrative specifications -
CPT II 1036F: Current tobacco non-user
OR
CPT II 4004F: Patient screened for tobacco use AND received tobacco cessation counseling (intervention counseling, pharmacotherapy, or both), if identified as a tobacco user
OR
CPT Category I code-Smoking and tobacco-use cessation counseling
- *The following codes are applicable if the patient screened positive for smoking/tobacco use and counseling was provided..
  - 99406: Smoking/tobacco counseling 3-10 minutes
  - 99407: Smoking/tobacco counseling greater than 10 minutes

**Denominator Statement**
All patients aged 18 years and older who were seen twice for any visits or who had at least one preventive care visit during the two-year measurement period
### Denominator Details

**Time Window:** 24 consecutive months

Note: for certain implementation programs that cannot support a 2 year measurement period, the measure can be reported within a 12 month period with a 24 month look back for the numerator details.

For Electronic Health Record specifications - See attached for PCPI eSpecification; HQMF eMeasure under development  
For Claims/Administrative specifications -  

CPT E/M Service code:

- **Two visits during the two year measurement period**
  
  99201, 99202, 99203, 99204, 99205 (Office/other outpatient services-new patient)  
  99212, 99213, 99214, 99215 (Office/other outpatient services-established patient)  
  97003, 97004 (Occupational therapy evaluations)  
  90801, 90802 (Psychiatric diagnostic or evaluative interview)  
  90804, 90805, 90806, 90807, 90808, 90809, 90810, 90811, 90812, 90813, 90814, 90815 (Psychiatric therapeutic procedures-office or other outpatient)  
  90845, 90862 (Other Psychotherapy)  
  96150, 96151, 96152 (Health and Behavior Assessment/Intervention)  

OR

CPT E/M Service Code:

- **One preventive care visit during the two year measurement period**
  
  99385, 99386, 99387 (Initial comprehensive preventive medicine-new patient)  
  99395, 99396, 99397 (Initial comprehensive preventive medicine-established patient)  
  99401, 99402, 99403, 99404 (Preventive medicine, Individual Counseling)  
  99411, 99412 (Preventive medicine, Group Counseling)  
  99420 (Other preventive medicine services-administration and interpretation of health risk assmt)  
  99429 (Unlisted preventive)  

OR

G-codes for annual wellness visit  
G0438, G0439

### Exclusions

**Documentation of medical reason(s) for not screening for tobacco use (eg, limited life expectancy)**

**Exclusion Details**

The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For measure 0028, exceptions may include medical reason(s) (eg, limited life expectancy) for not screening for tobacco use. Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:

For Electronic Health Record specifications - See attached for PCPI eSpecification; HQMF eMeasure under development  
For Claims/Administrative specifications -  

CPT II 4004F–1P: Documentation of medical reason(s) for not screening for tobacco use (eg, limited life expectancy, or other medical reason)

### Risk Adjustment

No risk adjustment or risk stratification
<table>
<thead>
<tr>
<th><strong>0028 Preventive Care &amp; Screening: Tobacco Use: Screening &amp; Cessation Intervention</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stratification</strong> We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
</tr>
<tr>
<td><strong>Type Score</strong> Rate/proportion better quality = higher score</td>
</tr>
<tr>
<td><strong>Algorithm</strong> To calculate performance rates:</td>
</tr>
<tr>
<td>1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).</td>
</tr>
<tr>
<td>2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.</td>
</tr>
<tr>
<td>3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator</td>
</tr>
<tr>
<td>4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: medical reason(s) (eg, limited life expectancy)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation.</td>
</tr>
<tr>
<td>--Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.</td>
</tr>
<tr>
<td>If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Calculation algorithm is included in data dictionary/code table attachment 2a1.30.</td>
</tr>
<tr>
<td><strong>Copyright/Disclaimer</strong> Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures. THE MEASURES ARE PROVIDED &quot;AS IS&quot; WITHOUT WARRANTY OF ANY KIND © 2008 American Medical Association. All Rights Reserved Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. THE SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. CPT® contained in the Measures specifications is copyright 2007 American Medical Association. See copyright statement above.</td>
</tr>
<tr>
<td>Status</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Steward</td>
</tr>
<tr>
<td>Description</td>
</tr>
<tr>
<td>Type</td>
</tr>
<tr>
<td>Data Source</td>
</tr>
<tr>
<td>Setting</td>
</tr>
<tr>
<td>Numerator Statement</td>
</tr>
<tr>
<td>Numerator Details</td>
</tr>
</tbody>
</table>
| **Denominator Statement** | Members 6 years and older as of the date of discharge who were discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal mental health diagnosis on or between January 1 and December 1 of the measurement year. The denominator for this measure is based on discharges, not members. Include all discharges for members who have more than one discharge on or between January 1 and December 1 of the measurement year.

Mental health readmission or direct transfer:
If the discharge is followed by readmission or direct transfer to an acute facility for a mental health principal diagnosis (within the 30-day follow-up period), count only the readmission discharge or the discharge from the facility to which the member was transferred. Although rehospitalization might not be for a selected mental health disorder, it is probably for a related condition.
Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year.
Exclude discharges followed by readmission or direct transfer to a nonacute facility for a mental health principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Refer to Table FUH-B for codes to identify nonacute care.
Non-mental health readmission or direct transfer:
Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. This includes an ICD-9-CM Diagnosis code or DRG code other than those in Tables MPT-A and MPT-B. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place. Refer for codes to identify nonacute care. |

| **Denominator Details** | Time Window: The measurement year
For commercial, Medicaid and Medicare product lines, and for members with a medical and mental health benefit who meet the continuous enrollment criteria of the date of discharge through 30 days after discharge.

Codes to Identify Mental Health Diagnosis
ICD-9-CM Diagnosis: 295–299, 300.3, 300.4, 301, 308, 309, 311–314
Table FUH0B: Codes to Identify Nonacute Care:
Hospice: UB Revenue: 0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 0659; UB Type of Bill: 81x, 82x; POS 34
SNF: UB Revenue: 019x, UB Type of Bill: 21x, 22x, 28x; POS 31, 32
Hospital transitional care: UB Type of Bill: 18x
Rehabilitation: UB Revenue: 0118, 0128, 0138, 0148, 0158
Intermediate care facility: POS 54
Respite: 0655
Residential substance abuse treatment facility: UB Revenue: 1002; POS 55
Psychiatric Residential Treatment Center: HCPCS: T2048, H0017-H0019; UB Revenue: 1001; POS 56
Comprehensive Inpatient Rehabilitation Facility: POS 61
Other nonacute care facilities that do not use the UB revenue or type of bill codes for billing (e.g., ICF, SNF) |

| **Exclusions** | Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year.
Exclude discharges followed by readmission or direct transfer to a nonacute facility for any mental health principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Refer for codes to identify nonacute care.
Non-mental health readmission or direct transfer: Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place. |

| **Exclusion Details** | Use Codes identified in Table FUH-B in 2a1.7. Denominator Details. |
### 0576 Follow-Up After Hospitalization for Mental Illness

<table>
<thead>
<tr>
<th>Risk Adjustment</th>
<th>No risk adjustment or risk stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stratification</td>
<td>N/A</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion better quality = higher score</td>
</tr>
</tbody>
</table>
| Algorithm       | Step 1. Determine the eligible population. The eligible population is all members who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.  
Step 2. Search administrative systems to identify numerator events for all members in the eligible population.  
Step 3. Calculate the rate. |

#### Copyright/Disclaimer
© 2012 by the National Committee for Quality Assurance  
1100 13th Street, NW, Suite 1000  
Washington, DC 20005  
These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.  
THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

### 1879 Adherence to Antipsychotics for Individuals with Schizophrenia

<table>
<thead>
<tr>
<th>Status</th>
<th>New Submission</th>
</tr>
</thead>
</table>
| Steward         | Centers for Medicare and Medicaid Services Other organizations: RAND Corporation: Soeren Mattke, DSc, Senior Scientist and Elizabeth Sloss, PhD.  
University of Florida College of Pharmacy: Almut Winterstein, PhD, Associate Professor, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy |
<p>| Description     | The measure calculates the percentage of individuals 18 years of age or greater as of the beginning of the measurement period with schizophrenia or schizoaffective disorder who are prescribed an antipsychotic medication, with adherence to the antipsychotic medication [defined as a Proportion of Days Covered (PDC)] of at least 0.8 during the measurement period (12 consecutive months). |
| Type            | Process |
| Data Source     | Administrative claims, Electronic Clinical Data : Pharmacy, Other |
| Level           | Clinician : Group/Practice, Population : State |
| Setting         | Ambulatory Care : Clinician Office, Behavioral Health/Psychiatric : Outpatient |
| Numerator Statement | Individuals with schizophrenia or schizoaffective disorder who filled at least two prescriptions for any antipsychotic medication and have a Proportion of Days Covered (PDC) for antipsychotic medications of at least 0.8. |</p>
<table>
<thead>
<tr>
<th>Numerator Details</th>
<th>Time Window: We define this as any time during the measurement period (12 consecutive months). The numerator is defined as individuals with a PDC of 0.8 or greater. The PDC is calculated as follows: PDC NUMERATOR: The PDC numerator is the sum of the days covered by the days’ supply of all antipsychotic prescriptions. The period covered by the PDC starts on the day the first prescription is filled (index date) and lasts through the end of the measurement period, or death, whichever comes first. For prescriptions with a days’ supply that extends beyond the end of the measurement period, count only the days for which the drug was available to the individual during the measurement period. If there are prescriptions for the same drug (generic name or 10-digit generic product identifier [GPI]) on the same date of service, keep the prescription with the largest days’ supply. If prescriptions for the same drug (generic name or GPI) overlap, then adjust the latest prescription start date to be the day after the previous fill has ended. PDC DENOMINATOR: The PDC denominator is the number of days from the first prescription date through the end of the measurement period, or death date, whichever comes first.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denominator Statement</td>
<td>Individuals at least 18 years of age as of the beginning of the measurement period with schizophrenia or schizoaffective disorder with at least two claims for any antipsychotic medication during the measurement period (12 consecutive months).</td>
</tr>
</tbody>
</table>
## 1879 Adherence to Antipsychotics for Individuals with Schizophrenia

<table>
<thead>
<tr>
<th>CPT:</th>
<th>UB-92 revenue:</th>
<th>WITH</th>
<th>POS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>90801, 90802, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99291</td>
<td>0961</td>
<td>NONACUTE INPATIENT SETTING</td>
<td>23</td>
</tr>
<tr>
<td>99304-99310, 99315, 99318, 99324-99328, 99334-99337</td>
<td>UB-92 revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x, 1000, 1001, 1003-1005</td>
<td>OR</td>
<td>CPT: 90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99291</td>
</tr>
<tr>
<td>90816-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99291</td>
<td>UB-92 revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 0987,080x</td>
<td>OR</td>
<td>CPT: 90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291</td>
</tr>
</tbody>
</table>

* CPT ©2010 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

The following are the oral antipsychotic medications by Class for the denominator. The route of administration includes all oral formulations of the medications listed below.

**TYPICAL ANTIPSYCHOTIC MEDICATIONS:**
- chlorpromazine
- fluphenazine
- haloperidol
- loxapine
- molindone
- perphenazine
- perphenazine-amitriptyline
- pimozide
- prochlorperazine
- thioridazine
- thiothixene
- trifluoperazine

**ATYPICAL ANTIPSYCHOTIC MEDICATIONS:**
- aripiprazole
- asenapine
- clozapine
- olanzapine
- olanzapine-fluoxetine
### 1879 Adherence to Antipsychotics for Individuals with Schizophrenia

<table>
<thead>
<tr>
<th>iloperidone</th>
<th>lurasidone</th>
<th>paliperidone</th>
<th>quetiapine</th>
<th>risperidone</th>
<th>ziprasidone</th>
</tr>
</thead>
</table>

The following are the long-acting (depot) injectable antipsychotic medications by Class for the denominator. The route of administration includes all injectable and intramuscular formulations of the medications listed below.

**TYPICAL ANTIPSYCHOTIC MEDICATIONS:**
- fluphenazine decanoate (J2680)
- haloperidol decanoate (J1631)

**ATYPICAL ANTIPSYCHOTIC MEDICATIONS:**
- olanzapine pamoate (J2358)
- paliperidone palmitate (J2426)
- risperidone microspheres (J2794)

Note: Since the days’ supply variable is not reliable for long-acting injections in administrative data, the days’ supply is imputed as listed below for the long acting (depot) injectable antipsychotic medications billed under Part D and Part B:
- fluphenazine decanoate (J2680) – 28 days’ supply
- haloperidol decanoate (J1631) – 28 days’ supply
- olanzapine pamoate (J2358) – 28 days’ supply
- paliperidone palmitate (J2426) – 28 days’ supply
- risperidone microspheres (J2794) – 14 days’ supply

**Exclusions**

We excluded the following individuals from the denominator:

**EXCLUSION**
- Individuals with any diagnosis of dementia during the measurement period

**Exclusion Details**

Individuals with any diagnosis of dementia are identified with the diagnosis codes listed below.

**CODES USED TO IDENTIFY DEMENTIA:**
- **ICD-9-CM:** 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 290.43, 290.8, 290.9, 291.2, 294.10, 294.11, 330.1, 331.0, 331.19, 331.82
- **ICD-10-CM:** E75.00, E75.01, E75.02, E75.09, E75.10, E75.11, E75.19, E75.4, F01.50, F01.51, F02.80, F02.81, F03, F05, F10.27, G30.0, G30.1, G30.8, G30.9, G31.09, G31.83

**Risk Adjustment**

No risk adjustment or risk stratification

**Stratification**

Depending on the operational use of the measure, measure results will be stratified by:
- State
- Physician Group*
- Age – Divided into 6 categories: 18-24, 25-44, 45-64, 65-74, 75-84, 85+ years
- Race/Ethnicity
- Dual Eligibility

*See attachment referenced in Sec 2.a.1.21 for the physician group attribution methodology used for this measure.

**Type Score**

Rate/proportion

**Algorithm**

Adherence to antipsychotic medications for individuals with schizophrenia is calculated as follows:

Obtain Medicare administrative claims data and related files as described in detail in Section 2a1.26.
Denominator: Individuals at least 18 years of age as of the beginning of the measurement period with schizophrenia or schizoaffective disorder with at least two claims for any antipsychotic medication during the measurement period (12 consecutive months).

Create Denominator:
1. Pull individuals who are 18 or older as of January 1 of the measurement period.
2. Include individuals who were continuously enrolled in Part D coverage during the measurement year, with no more than a 1-month gap in enrollment during the measurement year.
3. Include individuals who had no more than a 1-month gap in Part A enrollment, no more than a 1-month gap in Part B enrollment, and no more than 1 month of HMO [Health Maintenance Organization] enrollment during the current measurement year (fee-for-service [FFS] individuals only).
4. Of those individuals identified in Step 3, keep individuals who had at least 2 encounters with a diagnosis of schizophrenia with different dates of service in an outpatient setting, emergency department setting, or nonacute inpatient setting during the measurement period;
Or
Individuals who had at least 1 encounter with a diagnosis of schizophrenia in an acute inpatient setting during the measurement period.
5. For the individuals identified in Step 4, extract Part D claims for any antipsychotic medication during the measurement period.
6. Of the individuals identified in Step 5, exclude those who did not have at least 2 claims for any antipsychotic medication on different dates of service (identified by having at least 2 Part D claims with the specific codes) during the measurement year.
7. Exclude those individuals with a diagnosis of dementia during the measurement period.

Numerator: Individuals with schizophrenia or schizoaffective disorder who filled at least two prescriptions for any antipsychotic medication and have a Proportion of Days Covered (PDC) for antipsychotic medications of at least 0.8.

Of the individuals in the denominator, calculate the PDC for each individual according to the following methods:
1. Determine the individual’s measurement period, defined as the number of days from the index date through the end of the measurement period, or death, whichever comes first. The index date is the date of the first prescription in the measurement period.
2. Within the measurement period, count the days the individual was covered by at least one antipsychotic drug based on the prescription fill date and days of supply.
   a. Pull Part D antipsychotic claims for individuals in the denominator. Attach the drug ID and the generic name to the dataset.
   b. Sort and de-duplicate claims by beneficiary ID, service date, generic name, and descending days’ supply. If prescriptions for the same drug (generic name or 10-digit generic product identifier [GPI]) are dispensed on the same date of service for an individual, keep the dispensing with the largest days’ supply.
   c. Calculate the number of days covered by antipsychotic drug therapy per individual.
      i. For prescriptions with a days’ supply that extends beyond the end of the measurement period, count only the days for which the drug was available to the individual during the measurement period.
      ii. If prescriptions for the same drug (generic name or GPI) overlap, then adjust the latest prescription start date to be the day after the previous fill has ended.
      iii. If prescriptions for different drugs (different generic names or GPIs) overlap, do not adjust the prescription start date.
3. Calculate the PDC for each individual. Divide the number of covered days found in Step 2 by the number of days in the individual’s measurement period found in Step 1.

An example of SAS code for Steps 1-3 was adapted from Pharmacy Quality Alliance (PQA) and is also available at the URL: http://www2.sas.com/proceedings/forum2007/043-2007.pdf.

The algorithm regarding the physician group attribution is provided in the attachment below in Section 2a1.21.
### 1879 Adherence to Antipsychotics for Individuals with Schizophrenia

| Copyright/Disclaimer | Not Applicable, the measure is in the public domain. |

### 1927 Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

<table>
<thead>
<tr>
<th>Status</th>
<th>New Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>National Committee for Quality Assurance Other organizations: Mathematica Policy Research, Inc.</td>
</tr>
<tr>
<td>Description</td>
<td>The percentage of individuals 25 – 64 years of age with schizophrenia or bipolar disorder who were prescribed any antipsychotic medication who received a cardiovascular health screening during the measurement year.</td>
</tr>
<tr>
<td>Type</td>
<td>Process</td>
</tr>
<tr>
<td>Data Source</td>
<td>Administrative claims Not applicable.</td>
</tr>
<tr>
<td>Level</td>
<td>Population : State</td>
</tr>
<tr>
<td>Setting</td>
<td>Other Any outpatient setting represented with Medicaid claims data</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>One or more LDL-C screenings.</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: The measurement year. One or more LDL-C screenings performed during the measurement year defined by the following: CPT: 80061, 83700, 83701, 83704, 83721 CPT Category II: 3048F, 3049F, 3050F LOINC: 2089-1, 12773-8, 13457-7, 18261-8, 18262-6, 22748-8, 39469-2, 49132-4, 55440-2</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>Adults age 25 and older as of December 31 of the measurement year with a diagnosis of schizophrenia or bipolar disorder who were prescribed any antipsychotic medication.</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>Time Window: The measurement year. -Medicaid beneficiaries 25 – 64 years of age as of December 31 of the measurement year -Two separate claims with schizophrenia or bipolar disorder as a primary diagnosis or one inpatient claim with schizophrenia or bipolar disorder as a primary diagnosis</td>
</tr>
<tr>
<td>Exclusions</td>
<td>Individuals are excluded from the denominator if they were discharged alive for a coronary artery bypass graft or percutaneous coronary intervention (these events may occur in the measurement year or year prior to the measurement year), or diagnosed with ischemic vascular disease (this diagnosis must appear both the measurement year and the year before the measurement year), chronic heart failure, or had a prior myocardial infarction (identified in the measurement year or as far back as possible.).</td>
</tr>
</tbody>
</table>
**1927 Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications**

| **Exclusion Details** | Coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI). Individuals discharged alive for CABG or PCI in the measurement year or the year prior to the measurement year. Refer to (Table–E) and use codes for PCI and CABG only. CABG cases should be from inpatient claims/encounters only. Include all cases of PCI, regardless of setting (e.g., inpatient, outpatient, ED).

Ischemic vascular disease (IVD). Individuals who met at least one of the following criteria during both the measurement year and the year before the measurement year. Criteria need not be the same across both years.

- At least one outpatient visit (Table–F) with an IVD diagnosis (Table–E), or
- At least one acute inpatient claim/encounter (Table–F) with an IVD diagnosis (Table–E)

Chronic heart failure (CHF). Individuals who had at least one encounter, in any setting, with a code to identify CHF. Refer to (Table–E) and use codes for CHF only. Look as far back as possible in the member’s history through December 31 of the measurement year.

Prior Myocardial infarction (MI). Individuals who had at least one encounter, in any setting, with any code to identify MI (Table–E). Look as far back as possible in the member’s history through December 31 of the measurement year.

***Table –E: Codes to identify AMI, PCI, CABG, and CHF:***

- **CABG (include only inpatient claims):**
  - CPT: 33510-33514, 33516-33519, 33521-33523, 33533-33536
  - HCPCS: S2205-S2209
  - ICD-9-CM Procedure: 36.1, 36.2

- **PCI:**
  - CPT: 92980, 92982, 92995
  - HCPCS: G0290
  - ICD-9-CM Procedure: 00.66, 36.06, 36.07

- **CHF:**
  - ICD-9-CM Diagnosis: 428

- **IVD:**

***Table –F: Codes to identify visit type:***

- **Outpatient:**
  - CPT: 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456
  - UB Revenue: 051x, 0520-0523, 0526-0529, 057x-059x, 0982, 0983

- **Acute Inpatient:**
  - CPT: 99201-99205, 99211-99215, 99217-99220, 99221-99223, 99231-99233, 99238, 99295, 99251-99255, 99291
  - UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 0987

**Risk Adjustment**
- No risk adjustment or risk stratification
- Not applicable.

**Stratification**
- Not applicable.

**Type Score**
- Rate/proportion better quality = higher score

**Algorithm**
1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.
2. Search administrative systems to identify numerator events for all individuals in the eligible population.
3. Calculate the rate.
<table>
<thead>
<tr>
<th>1927 Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Copyright/Disclaimer</strong></td>
</tr>
<tr>
<td>© 2012 by the National Committee for Quality Assurance</td>
</tr>
<tr>
<td>1100 13th Street, NW, Suite 1000</td>
</tr>
<tr>
<td>Washington, DC 20005</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td>New Submission</td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td>National Committee for Quality Assurance <strong>Other organizations:</strong> Mathematica Policy Research, Inc.</td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td>The percentage of individuals 25 – 64 years of age with schizophrenia or bipolar disorder, who were prescribed any antipsychotic medication, and who received a diabetes screening during the measurement year.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td>Administrative claims Not applicable.</td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td>Population : State</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
<tr>
<td>Other Any outpatient setting represented with Medicaid claims data</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
</tr>
<tr>
<td>One or more glucose or HbA1c tests performed during the measurement year.</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
</tr>
<tr>
<td><strong>Time Window:</strong> The measurement year.</td>
</tr>
<tr>
<td>One or more diabetes screenings during the measurement year defined by the following:</td>
</tr>
<tr>
<td>Glucose Test:</td>
</tr>
<tr>
<td>CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951</td>
</tr>
<tr>
<td>HbA1c Test: 83036, 83037</td>
</tr>
<tr>
<td>CPT Category II: 3044F, 3045F, 3046F</td>
</tr>
<tr>
<td>LOINC: 4548-4, 4549-2, 17856-6, 59261-8, 62388-4</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
</tr>
<tr>
<td>Adults age 25 years and older as of December 31 of the measurement year with a schizophrenia or bipolar disorder diagnosis and who were prescribed any antipsychotic medication.</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
</tr>
<tr>
<td><strong>Time Window:</strong> The measurement year.</td>
</tr>
<tr>
<td>Medicaid beneficiaries 25 – 64 years of age as of December 31 of the measurement year</td>
</tr>
<tr>
<td>Two separate claims with schizophrenia or bipolar disorder as a primary diagnosis or one inpatient claim with schizophrenia or bipolar disorder as a primary diagnosis</td>
</tr>
</tbody>
</table>
1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

**Exclusions**

Individuals are excluded from the denominator if they have diabetes (during the measurement year or the year prior to the measurement year).

There are two ways to identify individuals with diabetes: 1) pharmacy data or 2) claim/encounter data. Both methods should be used to identify the eligible population, but the individual only needs to be identified by one method to be included in the measure.

Pharmacy data. Individuals who were dispensed insulin or oral hypoglycemics/antihyperglycemics during the measurement year or year before the measurement year on an ambulatory basis.

Claim/encounter data. Individuals who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years.

Codes to identify diabetes:
ICD-9 CM Diagnosis: 250, 357.2, 362.0, 366.41, 648.0

Prescriptions to identify individuals with diabetes:
Alpha-glucosidase inhibitors: acarbose, miglitol
Amylin analogs: pramlintide
Antidiabetic combinations: glimepiride-pioglitazone, glimepiride-rosiglitazone, glipizide-metformin, glyburide-metformin, metformin-pioglitazone, metformin-rosiglitazone, metformin-sitagliptin, saxagliptin, insulin aspart, insulin aspart-insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, insulin inhalation, insulin isophane beef-pork, insulin isophane-human, insulin isophane-insulin regular, insulin lispro, insulin lispro-insulin lispro protamine, insulin regular human, insulin zinc human
Meglitinides: nateglinide, repaglinide
Miscellaneous antidiabetic agents: exenatide, liraglutide, metformin-repaglinide, sitagliptin
Sulfonylureas: acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide
Thiazolidinediones: pioglitazone, rosiglitazone

Codes to identify visit type:
Outpatient:
CPT: 92002, 92004, 92012, 92014, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456
UB Revenue: 051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983
Nonacute inpatient:
CPT: 99304-99310, 99315, 99316, 99324-99328, 99334-99337
UB Revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x
Acute inpatient: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291
UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987
ED:
CPT: 99281-99285
UB Revenue: 045x, 0981
<p>| Exclusion Details | There are two ways to identify individuals with diabetes: 1) pharmacy data or 2) claim/encounter data. Both methods should be used to identify the eligible population, but the individual only needs to be identified by one method to be included in the measure. Pharmacy data. Individuals who were dispensed insulin or oral hypoglycemics/anthyper-glycemics during the measurement year or year before the measurement year on an ambulatory basis. Claim/encounter data. Individuals who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years. Codes to identify diabetes: ICD-9 CM Diagnosis: 250, 357.2, 362.0, 366.41, 648.0 Prescriptions to identify individuals with diabetes: Alpha-glucosidase inhibitors: acarbose, miglitol Amylin analogs: pramlinitide Antidiabetic combinations insulin: glicepiride-pioglitazone, glimepiride-rosiglitazone, glipizide-metformin, glyburide-metformin, metformin-pioglitazone metformin-rosiglitazone metformin-sitagliptin, Saxagliptin, insulin aspart, insulin aspart-insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, insulin inhalation, insulin isophane beef-pork, insulin isophane human, insulin isophane-insulin regular, insulin lispro, insulin lispro-insulin lispro protamine, insulin regular human, insulin zinc human Meglitinides: nateglinide, repaglinide Miscellaneous antidiabetic agents: exenatide, liraglutide, Metformin-repaglinide sitagliptin Sulfonylureas: acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide tolatamide, tolbutamide Thiazolidinediones: pioglitazone, rosiglitazone Codes to identify visit type: Outpatient: CPT: 92002, 92004, 92012, 92014, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456; UB Revenue: 051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983 Nonacute inpatient: CPT: 99304-99310, 99315, 99316, 99324-99328, 99334-99337; UB Revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x Acute inpatient: CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291; UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987 ED: CPT: 99281-99285; UB Revenue: 045x, 0981 |
| Risk Adjustment | No risk adjustment or risk stratification Not applicable. |
| Stratification | Not applicable. |
| Type Score | Rate/proportion better quality = higher score |
| Algorithm | 1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement. 2. Search administrative systems to identify numerator events for all individuals in the eligible population. 3. Calculate the rate. |
| Copyright/Disclaimer | © 2012 by the National Committee for Quality Assurance 1100 13th Street, NW, Suite 1000 Washington, DC 20005 |</p>
<table>
<thead>
<tr>
<th><strong>1933 Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
</tr>
</tbody>
</table>
| **Numerator Details** | **Time Window:** The measurement year.  
Codes to identify monitoring test:  
CPT: 80061, 83700, 83701, 83704, 83721  
CPT Category II: 3048F, 3049F, 3050F  
LOINC: 2089-1, 12773-8, 13457-7, 18261-8, 18262-6, 22748-8, 39469-2, 49132-4, 55440-2 |
| **Denominator Statement** | Adults 25 years and older as of December 31 of the measurement year with a diagnosis of schizophrenia and cardiovascular disease. |
| **Denominator Details** | **Time Window:** The measurement year.  
-Medicaid beneficiaries 25 – 64 years of age as of December 31 of the measurement year  
-Two separate claims with schizophrenia as a primary diagnosis or one inpatient claim with schizophrenia or as a primary diagnosis in the measurement year and diagnosis |
| **Exclusions** | Not applicable. |
| **Risk Adjustment** | No risk adjustment or risk stratification Not applicable. |
| **Stratification** | Not applicable. |
| **Type Score** | Rate/proportion better quality = higher score |
| **Algorithm** | 1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.  
2. Search administrative systems to identify numerator events for all individuals in the eligible population.  
3. Calculate the rate. |
| **Copyright/Disclaimer** | © 2012 by the National Committee for Quality Assurance  
1100 13th Street, NW, Suite 1000  
Washington, DC 20005 |
<table>
<thead>
<tr>
<th><strong>1934 Diabetes monitoring for people with diabetes and schizophrenia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
</tr>
</tbody>
</table>
| **Numerator Details** | **Time Window:** The measurement year.  
One or more HbA1c tests and one or more LDL-C tests performed during the measurement year defined by the following:  
Codes to identify HbA1c Test:  
CPT: 83036, 83037  
CPT Category II: 3044F, 3045F, 3046F  
Codes to identify LDL-C screening:  
CPT: 80061, 83700, 83701, 83704, 83721  
CPT Category II: 3048F, 3049F, 3050F |
| **Denominator Statement** | Adults age 25 years and older as of December 31 of the measurement year with a schizophrenia and diabetes diagnosis. |
| **Denominator Details** | **Time Window:** The measurement year.  
-Medicaid beneficiaries 25 – 64 years of age as of December 31 of the measurement year  
-Two separate claims with schizophrenia as a primary diagnosis or one inpatient claim with schizophrenia or as a primary diagnosis in the measurement year and diagnosis |
| **Exclusions** | Not applicable. |
| **Exclusion Details** | Not applicable. |
| **Risk Adjustment** | No risk adjustment or risk stratification |
| **Stratification** | Not applicable. |
| **Type Score** | Rate/proportion better quality = higher score |
| **Algorithm** | 1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.  
2. Search administrative systems to identify numerator events for all individuals in the eligible population.  
3. Calculate the rate. |
| **Copyright/Disclaimer** | © 2012 by the National Committee for Quality Assurance  
1100 13th Street, NW, Suite 1000  
Washington, DC 20005 |
### 1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)

<table>
<thead>
<tr>
<th>Status</th>
<th>New Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>National Committee for Quality Assurance Other organizations: Mathematica Policy Research, Inc.</td>
</tr>
</tbody>
</table>
| Description  | The percentage of discharges for individuals 25 – 64 years of age who were hospitalized for treatment of schizophrenia and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported.  
• The percentage of individuals who received follow-up within 30 days of discharge  
• The percentage of individuals who received follow-up within 7 days of discharge |
| Type         | Process |
| Data Source  | Administrative claims Not applicable. |
| Level        | Population : State |
| Setting      | Other Any outpatient setting represented with Medicaid claims data |

#### Numerator Statement
- **30-Day Follow-Up:** An outpatient visit, intensive outpatient encounter or partial hospitalization (Table–C) with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.
- **7-Day Follow-Up:** An outpatient visit, intensive outpatient encounter or partial hospitalization (Table–C) with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.

#### Numerator Details
- **Time Window:** The measurement year.  
Follow-up visits identified by the following CPT or HCPCS codes must be with a mental health practitioner:  
Follow-up visits identified by the following CPT/POS codes must be with a mental health practitioner:  
CPT: 90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876  
WITH  
POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 33, 49, 50, 52, 53, 71, 72  
CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255  
WITH  
POS: 52, 53  
The organization does not need to determine practitioner type for follow-up visits identified by the following UB revenue codes:  
UB Revenue: 0513, 0900-0905, 0907, 0911-0917, 0919  
Visits identified by the following revenue codes must be with a mental health practitioner or in conjunction with a diagnosis code:  
0510, 0515-0517, 0519-0523, 0526-0529, 0982, 0983.

#### Denominator Statement
- Adults 25 – 64 years of age of December 31 of the measurement year  
Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal schizophrenia diagnosis.

#### Denominator Details
- **Time Window:** The measurement year.  
-Medicaid beneficiaries age 25 years and older as of December 31 of the measurement year; no upper age limit  
-Two separate claims with schizophrenia as a primary diagnosis or one inpatient claim with schizophrenia as a primary diagnosis and a prescription.
### Exclusions

**Schizophrenia readmission or direct transfer:** If the discharge is followed by readmission or direct transfer to an acute facility for a schizophrenia diagnosis within the 30-day follow-up period, count only the readmission discharge or the discharge from the facility to which the member was transferred. Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year. Exclude discharges followed by readmission or direct transfer to a nonacute facility for a schizophrenia diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place.

**Non-mental health readmission or direct transfer:** Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place.

**Exclusion Details**

Exclude discharges followed by readmission or direct transfer to a nonacute facility for a schizophrenia principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place.

**Codes to identify Nonacute Care:**

- **Hospice:**
  - UB Revenue: 0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 0659
  - UB Type of Bill: 81x, 82x
  - POS: 34

- **SNF:**
  - UB Revenue: 019x
  - UB Type of Bill: 21x, 22x, 28x
  - POS: 31, 32

- **Hospital transitional care, swing bed or rehabilitation:**
  - UB Type of Bill: 18x

- **Rehabilitation:**
  - UB Revenue: 0118, 0128, 0138, 0148, 0158

- **Respite:**
  - UB Revenue: 0655

- **Intermediate care facility:**
  - POS: 54

- **Residential substance abuse treatment facility:**
  - UB Revenue: 1002
  - POS: 55

- **Psychiatric residential treatment center:**
  - HCPCS: T2048, H0017-H0019
  - UB Revenue: 1001
  - POS: 56

- **Comprehensive inpatient rehabilitation facility:**
  - POS: 61

### Risk Adjustment

No risk adjustment or risk stratification

Not applicable.

### Stratification

Not applicable.

### Type Score

Rate/proportion better quality = higher score

### Algorithm

1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.
2. Search administrative systems to identify numerator events for all individuals in the eligible population.
3. Calculate the rate.
Appendix B – Steering Committee

Peter Briss, MD, MPH (Co-Chair)

Medical Director, National Center for Chronic Disease Prevention and Health Promotion

Centers for Disease Control and Prevention

Harold Pincus, MD (Co-Chair)

Vice Chair, Department of Psychiatry, Columbia University

Colleen Barry, MPP, PhD

Associate Professor, Johns Hopkins Bloomberg School of Public Health

Caroline Carney-Doebbeling, MD, MSc, FAPM

Chief Medical Officer, MDwise, Inc.

Mady Chalk, PhD

Director, Treatment Research Institute

David Einzig, MD

Physician, Children’s Hospitals and Clinics of Minnesota

Nancy Hanrahan, RN, PhD

Associate Professor, University of Pennsylvania School of Nursing

Emma Hoo

Director of Value Based Purchasing, Pacific Business Group on Healthcare

Dolores Kelleher, MS, DMH

Principal, D. Kelleher Consulting

Parinda Khatri, PhD

Director, Integrated Care, Cherokee Health Systems

Michael Lardiere, LCSW

Vice President, The National Council for Community Behavioral Health Care

David Mancuso, PhD

Senior Research Supervisor, Washington State Department of Social and Health Services
Tami Mark, MBA, PhD

Senior Director, Thomson Reuters Healthcare, Inc.

Bernadette Melyn, PhD, CPNP, PMHNP, FNAP, FAAN

Associate Vice President for Health Promotion, Chief Wellness Officer and Dean

College of Nursing, The Ohio State University

Madeline Naegle, APRN, BC, PhD, FAAN

Professor, and Director of WHO Collaborating Center in Geriatric Nursing Education

New York University College of Nursing

David Pating, MD

Chief, Addiction Medicine, Kaiser Permanente Medical Center

Karlene Phillips, BSN, RN

Director, Inpatient Behavioral Health, Mayo Clinic Health System

Vanita Pindolia, PharmD, BCPS

Vice-President, Ambulatory Clinical Pharmacy Programs

Henry Ford Health System/Health Alliance Plan

Jeffrey Samet, MA, MPH, MD

Chief, Section of General Internal Medicine, Vice Chair for Public Health

Boston University School of Medicine

Lisa Shea, MD

Associate Medical Director, Quality and Regulation, Butler Hospital

Jeffrey Susman, MD

Dean, College of Medicine, Northeast Ohio Medical University

Lynn Wegner, MD

Director, Division of Developmental/Behavioral Pediatrics and Clinical Associate Professor

Department of Pediatrics, University of North Carolina

Mark Wolraich, MD
Professor of Pediatrics and Chief, Section of Developmental and Behavioral Pediatrics

Oklahoma University Health Sciences Center

Bonnie Zima, MD, MPH

Professor-in-Residence, UCLA Center for Health Services and Society

Leslie Zun, MD

Chair, Department of Emergency Medicine, Mount Sinai Hospital

NQF Staff

Helen Burstin, MD, MPH

Senior Vice President, Performance Measures

Heidi Bossley, MBA, MSN

Vice President, Performance Measures

Angela J. Franklin, JD

Senior Director

Lauralei Dorian

Project Manager

Evan M. Williamson, MPH, MS

Project Analyst
### Appendix C – Related Measure Comparison Tables

#### Comparison of NQF #0003 and NQF #1932

<table>
<thead>
<tr>
<th></th>
<th><strong>0003 Bipolar Disorder: Assessment for diabetes</strong></th>
<th><strong>1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steward</strong></td>
<td>Center for Quality Assessment and Improvement in Mental Health</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients treated for bipolar disorder who are assessed for diabetes within 16 weeks after initiating treatment with an atypical antipsychotic agent.</td>
<td>The percentage of individuals 25 – 64 years of age with schizophrenia or bipolar disorder, who were prescribed any antipsychotic medication, and who received a diabetes screening during the measurement year.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Paper Records</td>
<td>Administrative claims Not applicable.</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Clinician : Individual</td>
<td>Population : State</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office, Behavioral Health/Psychiatric : Outpatient</td>
<td>Other Any outpatient setting represented with Medicaid claims data</td>
</tr>
</tbody>
</table>
| **Numerator Statement** | Assessment for diabetes must include documentation of one of the following:  
• Reference in chart that test was ordered and results or information about results was obtained  
OR  
• Lab results filed in chart or available in patient’s electronic medical record  
Reference: Tests used to screen/assess for diabetes: Preferred Fasting plasma glucose; Non-fasting plasma glucose; Glucose tolerance Also Accepted: Glycosylated hemoglobin (Hb A1c; glycated hemoglobin) Random glucose AND  
Timeframe: Test results/information from test conducted within 16 weeks after the initiation of a second generation atypical antipsychotic agent  
OR  
Measurement EXCLUSION FROM COMPLIANCE Issues  
Numerator criteria not applicable and exclusion from compliance as stated below:  
1.Documentation by physician that test was not clinically indicated for this patient  
OR  
2.Documentation that test was requested but patient failed to comply with request to obtain test | One or more glucose or HbA1c tests performed during the measurement year. |
<p>| Numerator Details | Time Window: The measurement year. One or more diabetes screenings during the measurement year defined by the following: Glucose Test: CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 HbA1c Test: 83036, 83037 CPT Category II: 3044F, 3045F, 3046F LOINC: 4548-4, 4549-2, 17856-6, 59261-8, 62388-4 |</p>
<table>
<thead>
<tr>
<th>Denominator Statement</th>
<th>0003 Bipolar Disorder: Assessment for diabetes</th>
<th>1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients 18 years of age or older with an initial or new episode of bipolar disorder AND Documentation of a diagnosis of bipolar disorder; to include at least one of the following: • Codes 296.0x; 296.1x; 296.4x; 296.5x; 296.6x; 296.7; 296.80; 296.81; 296.82; 296.89; 301.13 documented in body of chart, such as a pre-printed form completed by a clinician and/or codes documented in chart notes/forms OR • Diagnosis or Impression or “working diagnosis” documented in chart indicating bipolar disorder OR • Use of a screening/assessment tool for bipolar disorder with a score or conclusion that patient has bipolar disorder and documentation that this information is used to establish or substantiate the diagnosis AND Documentation of treatment with an atypical antipsychotic agent. (See reference list below) Note: It is not the intent to indicate preferred pharmacotherapy. The reference list is inclusive of those atypical antipsychotic medications that are reasonably construed to be appropriate in accordance with current guidelines. (Reference list of medications also included in data collection form) Atypical Antipsychotic Agents • aripiprazole • quetiapine • clozapine • risperidone • olanzapine • ziprasidone • olanzapine-fluoxetine (combination) None. New diagnosis” or a “new episode,” is defined as cases where the patient has not been involved in active treatment for 6 months. Active treatment includes being hospitalized or under the out-patient care of a physician.</td>
<td>Adults age 25 years and older as of December 31 of the measurement year with a schizophrenia or bipolar disorder diagnosis and who were prescribed any antipsychotic medication.</td>
<td></td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td><strong>0003 Bipolar Disorder: Assessment for diabetes</strong></td>
<td><strong>1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</strong></td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Time Window:</strong> Patients 18 years of age or older with an initial or new episode of bipolar disorder AND Documentation of a diagnosis of bipolar disorder; to include at least one of the following:</td>
<td><strong>Time Window:</strong> The measurement year.</td>
<td><strong>Time Window:</strong> The measurement year.</td>
</tr>
<tr>
<td>• Codes 296.0x; 296.1x; 296.4x; 296.5x; 296.6x; 296.7; 296.80; 296.81; 296.82; 296.89; 301.13 documented in body of chart, such as a pre-printed form completed by a clinician and/or codes documented in chart notes/forms</td>
<td></td>
<td>- Medicaid beneficiaries 25 – 64 years of age as of December 31 of the measurement year</td>
</tr>
<tr>
<td>or</td>
<td></td>
<td>- Two separate claims with schizophrenia or bipolar disorder as a primary diagnosis or one inpatient claim with schizophrenia or bipolar disorder as a primary diagnosis</td>
</tr>
<tr>
<td>• Diagnosis or Impression or “working diagnosis” documented in chart indicating bipolar disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Use of a screening/assessment tool for bipolar disorder with a score or conclusion that patient has bipolar disorder and documentation that this information is used to establish or substantiate the diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and Documentation of treatment with an atypical antipsychotic agent. (See reference list below) Note: It is not the intent to indicate preferred pharmacotherapy. The reference list is inclusive of those atypical antipsychotic medications that are reasonably construed to be appropriate in accordance with current guidelines. (Reference list of medications also included in data collection form)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atypical Antipsychotic Agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• aripiprazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• quetiapine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• clozapine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• risperidone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• olanzapine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ziprasidone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• olanzapine-fluoxetine (combination)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None. New diagnosis” or a “new episode,” is defined as cases where the patient has not been involved in active treatment for 6 months. Active treatment includes being hospitalized or under the out-patient care of a physician.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>None.</td>
<td>Individuals are excluded from the denominator if they have diabetes (during the measurement year or the year prior to the measurement year). There are two ways to identify individuals with</td>
</tr>
</tbody>
</table>
### 0003 Bipolar Disorder: Assessment for diabetes

### 1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications

Diabetes: 1) pharmacy data or 2) claim/encounter data. Both methods should be used to identify the eligible population, but the individual only needs to be identified by one method to be included in the measure.

Pharmacy data. Individuals who were dispensed insulin or oral hypoglycemics/antihyperglycemics during the measurement year or year before the measurement year on an ambulatory basis.

Claim/encounter data. Individuals who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years.

Codes to identify diabetes:

- ICD-9 CM Diagnosis: 250, 357.2, 362.0, 366.41, 648.0

Prescriptions to identify individuals with diabetes:

- Alpha-glucosidase inhibitors: acarbose, miglitol
- Amylin analogs: pramlinitide
- Antidiabetic combinations: glimepiride-pioglitazone, glimepiride-rosiglitazone, glipizide-metformin, glyburide-metformin, metformin-pioglitazone, metformin-rosiglitazone, metformin-sitagliptin, saxagliptin, insulin aspart, insulin aspart-insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, insulin inhalation, insulin isophane beef-pork, insulin isophane human, insulin isophane-insulin regular, insulin lispro, insulin lispro-insulin lispro protamine, insulin regular human, insulin zinc human
- Meglitinides: nateglinide, repaglinide
- Miscellaneous antidiabetic agents: exenatide, liraglutide, metformin-repaglinide, sitagliptin
- Sulfonylureas: acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide
- Thiazolidinediones: pioglitazone, rosiglitazone

Codes to identify visit type:

**Outpatient:**
- UB Revenue: 051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983
### Exclusion Details

There are two ways to identify individuals with diabetes: 1) pharmacy data or 2) claim/encounter data. Both methods should be used to identify the eligible population, but the individual only needs to be identified by one method to be included in the measure.

**Pharmacy data.** Individuals who were dispensed insulin or oral hypoglycemics/antihyperglycemics during the measurement year or year before the measurement year on an ambulatory basis.

**Claim/encounter data.** Individuals who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years.

**Codes to identify diabetes:**
- ICD-9 CM Diagnosis: 250, 357.2, 362.0, 366.41, 648.0
- Prescriptions to identify individuals with diabetes:
  - Alpha-glucosidase inhibitors: acarbose, miglitol
  - Amylin analogs: pramlintide
  - Antidiabetic combinations insulin: glimepiride-pioglitazone, glimepiride-rosiglitazone, glipizide-metformin, glyburide-metformin, metformin-pioglitazone
  - Metformin-rosiglitazone metformin-sitagliptin, Saxagliptin, insulin aspart, insulin aspart-insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, insulin inhalation, insulin isophane beef-pork, insulin isophane human, insulin isophane-insulin regular, insulin lispro, insulin lispro-insulin lispro protamine, insulin regular human, insulin zinc human Meglitinides: nateglinide, repaglinide

---

### Table: 0003 Bipolar Disorder: Assessment for diabetes

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
</table>
| 1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications | Nonacute inpatient:  
CPT: 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337  
UB Revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x  
Acute inpatient: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291  
UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987  
ED:  
CPT: 99281-99285  
UB Revenue: 045x, 0981 |

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0003 Bipolar Disorder: Assessment for diabetes</td>
<td>Exclusion Details</td>
</tr>
</tbody>
</table>

**There are two ways to identify individuals with diabetes: 1) pharmacy data or 2) claim/encounter data. Both methods should be used to identify the eligible population, but the individual only needs to be identified by one method to be included in the measure.**

**Pharmacy data.** Individuals who were dispensed insulin or oral hypoglycemics/antihyperglycemics during the measurement year or year before the measurement year on an ambulatory basis.

**Claim/encounter data.** Individuals who had two face-to-face encounters, in an outpatient setting or nonacute inpatient setting, on different dates of service, with a diagnosis of diabetes, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years.

**Codes to identify diabetes:**
- ICD-9 CM Diagnosis: 250, 357.2, 362.0, 366.41, 648.0
- Prescriptions to identify individuals with diabetes:
  - Alpha-glucosidase inhibitors: acarbose, miglitol
  - Amylin analogs: pramlintide
  - Antidiabetic combinations insulin: glimepiride-pioglitazone, glimepiride-rosiglitazone, glipizide-metformin, glyburide-metformin, metformin-pioglitazone
  - Metformin-rosiglitazone metformin-sitagliptin, Saxagliptin, insulin aspart, insulin aspart-insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, insulin inhalation, insulin isophane beef-pork, insulin isophane human, insulin isophane-insulin regular, insulin lispro, insulin lispro-insulin lispro protamine, insulin regular human, insulin zinc human Meglitinides: nateglinide, repaglinide
<table>
<thead>
<tr>
<th>0003 Bipolar Disorder: Assessment for diabetes</th>
<th>1932 Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscellaneous antidiabetic agents: exenatide, liraglutide, Metformin-repaglinide sitagliptin</td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas: acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide tolazamide, tolbutamide</td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones: pioglitazone, rosiglitazone</td>
<td></td>
</tr>
<tr>
<td>Codes to identify visit type:</td>
<td></td>
</tr>
<tr>
<td>Outpatient: CPT: 92002, 92004, 92012, 92014, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456; UB Revenue: 051x, 0520-0523, 0526-0529, 057x-059x, 082x-085x, 088x, 0982, 0983</td>
<td></td>
</tr>
<tr>
<td>Nonacute inpatient: CPT: 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337; UB Revenue: 0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x</td>
<td></td>
</tr>
<tr>
<td>Acute inpatient: CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291; UB Revenue: 010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x, 021x, 072x, 080x, 0987</td>
<td></td>
</tr>
<tr>
<td>ED: CPT: 99281-99285; UB Revenue: 045x, 0981</td>
<td></td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td>Stratification</td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td>Type Score</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Rate/proportion better quality = higher score</td>
<td></td>
</tr>
<tr>
<td>Algorithm</td>
<td>1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.</td>
</tr>
<tr>
<td></td>
<td>2. Search administrative systems to identify numerator events for all individuals in the eligible population.</td>
</tr>
<tr>
<td></td>
<td>3. Calculate the rate.</td>
</tr>
<tr>
<td>Submission items</td>
<td>0003 Bipolar Disorder: Assessment for diabetes</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td><strong>5.1 Identified measures:</strong></td>
<td>5.1 Identified measures: 0003: Bipolar Disorder: Assessment for diabetes</td>
</tr>
<tr>
<td>5a.1 Are specs completely harmonized?</td>
<td>5a.1 Are specs completely harmonized? No</td>
</tr>
<tr>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact:</td>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact: The denominator for this measure includes bipolar disorder and schizophrenia while the NQF-endorsed measure only includes bipolar disorder. This measure includes an older population (25 years versus 18 years) as the ability to properly diagnose may become more apparent in older patients. The NQF-endorsed measure has a higher data collection burden as that measure is collected by claims and chart data while this measure is collected through claims only. The NQF-endorsed measure includes only atypical antipsychotics, while this measure includes both typical and atypical medications. Evidence suggests that both types of medications may increase the risk of diabetes (Gianfrancesco et al., 2002). Gianfrancesco, F.D., Grogg, A.L., Mahmoud, R.A., et al. (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry, 63, 920-30.</td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value:</td>
<td>5b.1 If competing, why superior or rationale for additive value: The denominator for this measure includes bipolar disorder and schizophrenia while the NQF-endorsed measure only includes bipolar disorder. This measure includes an older population (25 years versus 18 years) as the ability to properly diagnose may become more apparent in older patients. The NQF-endorsed measure may have a higher data collection burden as that measure is collected by claims and chart data, while this measure is collected through claims data only. The NQF-endorsed measure includes only atypical antipsychotics, while this measure includes both typical and atypical medications. Evidence suggests that both types of medications may increase the risk of diabetes (Gianfrancesco et al., 2002). Gianfrancesco, F.D., Grogg, A.L., Mahmoud, R.A., et al. (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry, 63, 920-30.</td>
</tr>
<tr>
<td>Steward</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of adult patients with diabetes aged 18-75 years receiving one or more A1c test(s) per year</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Electronic Clinical Data : Electronic Health Record, Paper Records</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>One or more HbA1c tests performed during the measurement year.</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: The measurement year Administrative Claims: CPT codes: 83036, 83037; CPT Category II: 3044F, 3045F, 3046F; LOINC: 4548-4, 4549-2, 17856-6 Medical Record Documentation: At a minimum, documentation in the medical record must include a note indicating the date on which the HbA1c test was performed and the result. Notation of the following in the medical record may be counted: -A1c -HbA1c -Hemoglobin A1c -Glycohemoglobin A1c -HgbA1c</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>0057 Diabetes: Hemoglobin A1c testing</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Patients 18-75 years of age as of December 31 of the measurement year who had a diagnosis of diabetes (type 1 or type 2). Patients with diabetes can be identified during the measurement year, or year prior to the measurement year through: •Pharmacy data: Patients who were prescribed insulin or oral hypoglycemics/antihyperglycemics on an ambulatory basis. Prescriptions to identify patients with diabetes include: insulin prescriptions (drug list is available) and oral hypoglycemics/antihyperglycemics prescriptions (drug list is available). •A Diagnosis of Diabetes on the Problem List or at least two visits with diabetes listed as a diagnosis. Presentation of Codes: Unless otherwise noted, codes are stated to the minimum specificity required. For example, if a three digit code is listed, it is valid as a three-, four- or five-digit code. When necessary, a code may be specified with an “x” which represents a required digit. For example ICD-9 CM diagnosis code 640.0x means that a fifth digit is required, but the fifth digit could be any number allowed by the coding manual.</td>
<td>Patients 18-75 years of age as of December 31 of the measurement year who had a diagnosis of diabetes (type 1 or type 2).</td>
</tr>
<tr>
<td>Denominator Details</td>
<td>0057 Diabetes: Hemoglobin A1c testing</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Time Window: The measurement year</td>
<td>Time Window: The measurement year</td>
</tr>
<tr>
<td>Patients with diabetes can be identified during the measurement year, or year prior to the measurement year through: Pharmacy data: Patients who were prescribed insulin or oral hypoglycemics/anti-hypoglycemics on an ambulatory basis. Prescriptions to identify patients with diabetes include: insulin prescriptions (drug list is available) and oral hypoglycemics/anti-hypoglycemics prescriptions (drug list is available). A Diagnosis of Diabetes on the Problem List or at least two visits with diabetes listed as a diagnosis.</td>
<td>Patients with diabetes can be identified during the measurement year, or year prior to the measurement year through: Pharmacy data: Patients who were prescribed insulin or oral hypoglycemics/anti-hypoglycemics on an ambulatory basis. Prescriptions to identify patients with diabetes include: insulin prescriptions (drug list is available) and oral hypoglycemics/anti-hypoglycemics prescriptions (drug list is available). A Diagnosis of Diabetes on the Problem List or at least two visits with diabetes listed as a diagnosis.</td>
</tr>
<tr>
<td>Presentation of Codes: Unless otherwise noted, codes are stated to the minimum specificity required. For example, if a three digit code is listed, it is valid as a three-, four- or five-digit code. When necessary, a code may be specified with an “x” which represents a required digit. For example ICD-9 CM diagnosis code 640.0x means that a fifth digit is required, but the fifth digit could be any number allowed by the coding manual.</td>
<td>Presentation of Codes: Unless otherwise noted, codes are stated to the minimum specificity required. For example, if a three digit code is listed, it is valid as a three-, four- or five-digit code. When necessary, a code may be specified with an &quot;x&quot; which represents a required digit. For example ICD-9 CM diagnosis code 640.0x means that a fifth digit is required, but the fifth digit could be any number allowed by the coding manual.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>Exclude patients with a diagnosis of polycystic ovaries on the problem list who did not have a diagnosis of diabetes on the problem list during the measurement year or year prior to the measurement year. Exclude patients with a diagnosis of gestational diabetes or steroid-induced diabetes on the problem list who did not have a diagnosis of diabetes on the problem list during the measurement year or the year prior to the measurement year.</td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>N/A</td>
</tr>
<tr>
<td>0057 Diabetes: Hemoglobin A1c testing</td>
<td>0063 Diabetes: Lipid profile</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
<td>No risk adjustment or risk stratification N/A</td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
<td>Not applicable.</td>
</tr>
<tr>
<td><strong>Type Score</strong></td>
<td>Rate/proportion better quality = higher score</td>
</tr>
</tbody>
</table>
| **Algorithm**                         | 1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.  
2. Search administrative systems to identify numerator events for all individuals in the eligible population.  
3. Calculate the rate. |
| **Submission items**                   | 5.1 Identified measures:  
5a.1 Are specs completely harmonized?  
5a.2 If not completely harmonized, identify difference, rationale, impact:  
5b.1 If competing, why superior or rationale for additive value: |
|                                       | 5.1 Identified measures:  
5a.1 Are specs completely harmonized?  
5a.2 If not completely harmonized, identify difference, rationale, impact:  
5b.1 If competing, why superior or rationale for additive value: |
|                                       | 5.1 Identified measures:  
5a.1 Are specs completely harmonized?  
5a.2 If not completely harmonized, identify difference, rationale, impact:  
5b.1 If competing, why superior or rationale for additive value: |

5a.1 Are specs completely harmonized?  
5a.2 If not completely harmonized, identify difference, rationale, impact:  
5b.1 If competing, why superior or rationale for additive value:  

- **5a.1 Are specs completely harmonized?**  
  - No

- **5a.2 If not completely harmonized, identify difference, rationale, impact:**  
  - The NQF-endorsed measure includes adults age 18 – 75 years of age who have received one or more HbA1c tests. This measure is focused on serious mental illness and includes patients with schizophrenia who are 25 years or older who have received an HbA1c and LDL-C test. The age cutoff for this measure was set at 25 years as diagnostic clarity may be more favorable in older patients with schizophrenia. The NQF-endorsed measure may have a higher data collection burden as the measure is specified to use claims, paper chart, or electronic medical records, while this measure strictly uses claims data.

- **5b.1 If competing, why superior or rationale for additive value:**  
  - No
## Comparison of NQF #0576 and #1937

<table>
<thead>
<tr>
<th><strong>0576 Follow-up After Hospitalization for Mental Illness</strong></th>
<th><strong>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steward</strong></td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>This measure assesses the percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported.</td>
</tr>
<tr>
<td><strong>Rate 1:</strong></td>
<td>The percentage of members who received follow-up within 30 days of discharge</td>
</tr>
<tr>
<td><strong>Rate 2:</strong></td>
<td>The percentage of members who received follow-up within 7 days of discharge</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Electronic Clinical Data: Electronic Health Record</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Health Plan, Clinician: Team, Integrated Delivery System, Population: County or city, National, Regional, State</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care: Clinician Office/Clinic, Urgent Care, Behavioral Health: Psychiatrist, Outpatient</td>
</tr>
</tbody>
</table>
| **Numerator Statement** | Rate 1: An outpatient visit, intensive outpatient encounter or partial hospitalization with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.  
Rate 2: An outpatient visit, intensive outpatient encounter or partial hospitalization with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge. | 30-Day Follow-Up: An outpatient visit, intensive outpatient encounter or partial hospitalization (Table–C) with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.  
7-Day Follow-Up: An outpatient visit, intensive outpatient encounter or partial hospitalization (Table–C) with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge. |
<table>
<thead>
<tr>
<th>Numerator Details</th>
<th>0576 Follow-up After Hospitalization for Mental Illness</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time Window</strong>:</td>
<td>Date of discharge through 30 days after discharge</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Include outpatient</td>
<td>0576 Follow-up After Hospitalization for Mental Illness</td>
<td>Follow-up visits identified by the following CPT or HCPCS codes must be with a mental health practitioner:</td>
</tr>
<tr>
<td>visits, intensive</td>
<td>Include outpatient visits, intensive outpatient</td>
<td>CPT: 90804-90815, 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99383-99387, 99393-99397, 99401-99404, 99411, 99412, 99510</td>
</tr>
<tr>
<td>hospitalizations</td>
<td>Codes to Identify Visits:</td>
<td>CPT: 90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90849, 90853, 90857, 90862, 90870, 90871, 90875, 90876 with POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24, 33, 49, 50, 52, 53, 71, 72</td>
</tr>
<tr>
<td>that occur on the</td>
<td>CPT: 90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90849, 90853, 90857, 90862, 90870, 90875, 90876 with POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24, 33, 49, 50, 52, 53, 71, 72</td>
<td></td>
</tr>
<tr>
<td>date of discharge.</td>
<td>CPT: 99221-99223, 99231-99233, 99238, 99239, 99251-99255 with POS 52, 53</td>
<td>The organization does not need to determine practitioner type for follow-up visits identified by the following UB revenue codes:</td>
</tr>
<tr>
<td>Include outpatient</td>
<td>The organization does not need to determine practitioner type for follow-up visits identified by the following UB revenue codes:</td>
<td></td>
</tr>
<tr>
<td>visits, intensive</td>
<td>UB Revenue: 0513, 0900-0905, 0907, 0911-0917, 0919,</td>
<td>UB Revenue: 0513, 0900-0905, 0907, 0911-0917, 0919</td>
</tr>
<tr>
<td>encounters or partial</td>
<td>Visits identified by the following revenue codes must be with a mental health practitioner or in conjunction with a diagnosis code from Table FUH-A.</td>
<td>Visits identified by the following revenue codes must be with a mental health practitioner or in conjunction with a diagnosis code:</td>
</tr>
<tr>
<td>hospitalizations</td>
<td>UB Revenue: 0510, 0515-0517, 0519-0523, 0526-0529, 077x, 0982, 0983</td>
<td>0510, 0515-0517, 0519-0523, 0526-0529, 0982, 0983</td>
</tr>
<tr>
<td>that occur on the</td>
<td>The organization does not need to determine practitioner type for follow-up visits identified by the following UB revenue codes:</td>
<td></td>
</tr>
<tr>
<td>date of discharge.</td>
<td>UB Revenue: 0513, 0900-0905, 0907, 0911-0917, 0919</td>
<td>UB Revenue: 0513, 0900-0905, 0907, 0911-0917, 0919</td>
</tr>
<tr>
<td>include all discharges for members who have more than one discharge on or between January 1 and December 1 of the measurement year.</td>
<td>Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal schizophrenia diagnosis.</td>
<td></td>
</tr>
</tbody>
</table>

**Numerator Details**

**Denominator Statement**

Members 6 years and older as of the date of discharge who were discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal mental health diagnosis on or between January 1 and December 1 of the measurement year. The denominator for this measure is based on discharges, not members. Include all discharges for members who have more than one discharge on or between January 1 and December 1 of the measurement year.

Adults 25 – 64 years of age of December 31 of the measurement year Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal schizophrenia diagnosis.
<table>
<thead>
<tr>
<th>0576 Follow-up After Hospitalization for Mental Illness</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Denominator Details</strong></td>
<td><strong>Time window</strong>: The measurement year.</td>
</tr>
<tr>
<td></td>
<td>- Medicaid beneficiaries age 25 years and older as of December 31 of the measurement year.</td>
</tr>
<tr>
<td></td>
<td>- Two separate claims with schizophrenia as a primary diagnosis or one inpatient claim with schizophrenia as a primary diagnosis and a prescription for any antipsychotic medication in the measurement year.</td>
</tr>
<tr>
<td></td>
<td>- 10 months continuous enrollment during the measurement year.</td>
</tr>
<tr>
<td></td>
<td>- Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal schizophrenia diagnosis on or between January 1 and December 1 of the measurement year.</td>
</tr>
<tr>
<td></td>
<td>- The denominator for this measure is based on discharges. Include all discharges for individuals who have more than one discharge on or between January 1 and December 1 of the measurement year.</td>
</tr>
<tr>
<td></td>
<td>Codes to Identify Schizophrenia Diagnosis:</td>
</tr>
<tr>
<td></td>
<td>ICD-9-CM Diagnosis: 295</td>
</tr>
<tr>
<td></td>
<td>ICD-10-CM Diagnosis: F20, F25.9</td>
</tr>
</tbody>
</table>

**Time Window**: The measurement year.
- For commercial, Medicaid and Medicare product lines, and for members with a medical and mental health benefit who meet the continuous enrollment criteria of the date of discharge through 30 days after discharge.
- For members with a medication benefit only, this requires 10 months of continuous enrollment during the measurement year.

**Codes to Identify Mental Health Diagnosis**
- ICD-10-CM Diagnosis: F20, F25.9

**Table FUH0B: Codes to Identify Nonacute Care**
- Hospice: UB Revenue: 0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 0659; UB Type of Bill: 81x, 82x; POS 34
- SNF: UB Revenue: 019x, UB Type of Bill: 21x, 22x, 28x; POS 31, 32
- Hospital transitional care: UB Type of Bill: 18x
- Rehabilitation: UB Revenue: 0118, 0128, 0138, 0148, 0158
- Intermediate care facility: POS 54
- Respite: 0655
- Residential substance abuse treatment facility: UB Revenue: 1002; POS 55
- Psychiatric Residential Treatment Center: HCPCS: T2048, H0017-H0019; UB Revenue: 1001; POS 56
- Comprehensive Inpatient Rehabilitation Facility: POS 61
- Other nonacute care facilities that do not use the UB revenue or type of bill codes for billing (e.g., ICF, SNF)
<table>
<thead>
<tr>
<th>Exclusions</th>
<th>0576 Follow-up After Hospitalization for Mental Illness</th>
<th>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year. Exclude discharges followed by readmission or direct transfer to a nonacute facility for any mental health principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Refer for codes to identify nonacute care. Non-mental health readmission or direct transfer: Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place.</td>
<td>Schizophrenia readmission or direct transfer: If the discharge is followed by readmission or direct transfer to an acute facility for a schizophrenia diagnosis within the 30-day follow-up period, count only the readmission discharge or the discharge from the facility to which the member was transferred. Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year. Exclude discharges followed by readmission or direct transfer to a nonacute facility for a schizophrenia diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Non-mental health readmission or direct transfer: Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place.</td>
<td></td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>Follow-up After Hospitalization for Mental Illness</td>
<td>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Use Codes identified in Table FUH-B in 2a1.7. Denominator Details.</td>
<td>Exclude discharges followed by readmission or direct transfer to a nonacute facility for a schizophrenia principal diagnosis within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Codes to identify Nonacute Care: Hospice: UB Revenue: 0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 0659 UB Type of Bill: 81x, 82x POS: 34 SNF: UB Revenue: 019x; UB Type of Bill: 21x, 22x, 28x; POS: 31, 32 Hospital transitional care, swing bed or rehabilitation: UB Type of Bill: 18x Rehabilitation: UB Revenue: 0118, 0128, 0138, 0148, 0158 Respite: UB Revenue: 0655 Intermediate care facility: POS: 54 Residential substance abuse treatment facility: UB Revenue: 1002 POS: 55 Psychiatric residential treatment center; HCPCS: T2048, H0017-H0019 UB Revenue: 1001 POS: 56 Comprehensive inpatient rehabilitation facility: POS: 61</td>
<td></td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification</td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td>Stratification</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion</td>
<td>Rate/proportion</td>
</tr>
<tr>
<td>Algorithm</td>
<td>0576 Follow-up After Hospitalization for Mental Illness</td>
<td>1937 Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Step 1. Determine the eligible population. The eligible population is all members who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.</td>
<td>1. Determine the eligible population. The eligible population is all individuals who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.</td>
<td></td>
</tr>
<tr>
<td>Step 2. Search administrative systems to identify numerator events for all members in the eligible population.</td>
<td>2. Search administrative systems to identify numerator events for all members in the eligible population.</td>
<td></td>
</tr>
<tr>
<td>Step 3. Calculate the rate.</td>
<td>3. Calculate the rate.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Submission</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1. If there are related measures (either same measure focus or target population) or competing measures (both the same measure focus and same target population), list the NQF # and title of all related and/or competing measures: N/A</td>
<td>5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s): Are the measure specifications completely harmonized? No</td>
<td></td>
</tr>
<tr>
<td>5b.1. If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible): N/A</td>
<td>5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden: The age cutoff for this measure was set at 25 years as diagnostic clarity is more favorable in older patients with schizophrenia. The NQF-endorsed measure is specified for health plans, while this new measure is specified for state populations. The NQF-endorsed measure may have a higher data collection burden as the measure is specified to use claims or electronic medical records, while this new measure strictly uses claims data.</td>
<td></td>
</tr>
</tbody>
</table>